Every	O
enhancer	O
works	O
with	O
every	O
promoter	B-DNA
for	O
all	O
the	O
combinations	O
tested	O
:	O
could	O
new	O
regulatory	O
pathways	O
evolve	O
by	O
enhancer	O
shuffling	O
?	O

The	O
promoters	B-DNA
and	O
enhancers	B-DNA
of	O
cell	O
type-specific	O
genes	O
are	O
often	O
conserved	O
in	O
evolution	O
,	O
and	O
hence	O
one	O
might	O
expect	O
that	O
a	O
given	O
enhancer	B-DNA
has	O
evolved	O
to	O
work	O
best	O
with	O
its	O
own	O
promoter	B-DNA
.	O

While	O
this	O
expectation	O
may	O
be	O
realized	O
in	O
some	O
cases	O
,	O
we	O
have	O
not	O
found	O
evidence	O
for	O
it	O
.	O

A	O
total	O
of	O
27	O
combinations	O
of	O
different	O
promoters	B-DNA
and	O
enhancers	B-DNA
were	O
tested	O
by	O
transfection	O
into	O
cultured	B-cell_line
cells	I-cell_line
.	O

We	O
found	O
that	O
the	O
relative	O
efficiency	O
of	O
the	O
enhancers	B-DNA
is	O
approximately	O
the	O
same	O
,	O
irrespective	O
of	O
the	O
type	O
of	O
promoter	B-DNA
used	O
,	O
i.e.	O
,	O
there	O
was	O
no	O
strong	O
preference	O
for	O
any	O
given	O
enhancer/	O
promoter	B-DNA
combination	O
.	O

Notably	O
,	O
we	O
do	O
not	O
see	O
particularly	O
strong	O
transcription	O
when	O
the	O
immunoglobulin	B-DNA
kappa	I-DNA
enhancer	I-DNA
(	O
or	O
the	O
immunoglobulin	B-DNA
heavy	I-DNA
chain	I-DNA
enhancer	I-DNA
)	O
is	O
used	O
to	O
activate	O
a	O
kappa	O
gene	O
promoter	B-DNA
.	O

We	O
propose	O
that	O
a	O
generally	O
permissive	O
enhancer/	O
promoter	B-DNA
interaction	O
is	O
of	O
evolutionary	O
benefit	O
for	O
higher	O
eukaryotes	O
:	O
by	O
enhancer	O
shuffling	O
,	O
genes	O
could	O
be	O
easily	O
brought	O
under	O
a	O
new	O
type	O
of	O
inducibility/cell	O
type	O
specificity	O
.	O

Volume	NULL
1	NULL
+	NULL
Number	NULL
1	NULL
+	NULL
April	NULL
1991	NULL
GENE	NULL
EXPRESSION	NULL
Every	NULL
enhancer	NULL
works	NULL
with	NULL
every	NULL
promoter	NULL
for	NULL
all	NULL
the	NULL
combinations	NULL
tested	NULL
:	NULL
could	NULL
new	NULL
regulatory	NULL
pathways	NULL
evolve	NULL
by	NULL
enhancer	NULL
shuffling	NULL
?	NULL

Milko	NULL
Kermekchiev	NULL
,	NULL
Monica	NULL
Pettersson	NULL
,	NULL
Patrick	NULL
Matthias	NULL
and	NULL
Walter	NULL
Schaffner	NULL
Institute	NULL
for	NULL
Molecular	NULL
Biology	NULL
II	NULL
,	NULL
University	NULL
of	NULL
Zurich	NULL
The	NULL
promoters	NULL
and	NULL
enhancers	NULL
of	NULL
cell	NULL
type-specific	NULL
genes	NULL
are	NULL
often	NULL
conserved	NULL
in	NULL
evolution	NULL
,	NULL
and	NULL
hence	NULL
one	NULL
might	NULL
expect	NULL
that	NULL
a	NULL
given	NULL
enhancer	NULL
has	NULL
evolved	NULL
to	NULL
work	NULL
best	NULL
with	NULL
its	NULL
own	NULL
promoter	NULL
.	NULL

While	NULL
this	NULL
expectation	NULL
may	NULL
be	NULL
realized	NULL
in	NULL
some	NULL
cases	NULL
,	NULL
we	NULL
have	NULL
not	NULL
found	NULL
evidence	NULL
for	NULL
it	NULL
.	NULL

A	NULL
total	NULL
of	NULL
27	NULL
combinations	NULL
of	NULL
different	NULL
promoters	NULL
and	NULL
enhancers	NULL
were	NULL
tested	NULL
by	NULL
transfection	NULL
into	NULL
cultured	NULL
cells	NULL
.	NULL

We	NULL
found	NULL
that	NULL
the	NULL
relative	NULL
efficiency	NULL
of	NULL
the	NULL
enhancers	NULL
is	NULL
approximately	NULL
the	NULL
same	NULL
,	NULL
irrespective	NULL
of	NULL
the	NULL
type	NULL
of	NULL
promoter	NULL
used	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
there	NULL
was	NULL
no	NULL
strong	NULL
preference	NULL
for	NULL
any	NULL
given	NULL
enhancer/promoter	NULL
combination	NULL
.	NULL

Notably	NULL
,	NULL
we	NULL
do	NULL
not	NULL
see	NULL
particularly	NULL
strong	NULL
transcription	NULL
when	NULL
the	NULL
immunoglobulin	NULL
kappa	NULL
enhancer	NULL
(	NULL
or	NULL
the	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
enhancer	NULL
)	NULL
is	NULL
used	NULL
to	NULL
activate	NULL
a	NULL
kappa	NULL
gene	NULL
promoter	NULL
.	NULL

We	NULL
propose	NULL
that	NULL
a	NULL
generally	NULL
permissive	NULL
enhancer/promoter	NULL
interaction	NULL
is	NULL
of	NULL
evolutionary	NULL
benefit	NULL
for	NULL
higher	NULL
eukaryotes	NULL
:	NULL
by	NULL
enhancer	NULL
shuffling	NULL
,	NULL
genes	NULL
could	NULL
be	NULL
easily	NULL
brought	NULL
under	NULL
a	NULL
new	NULL
type	NULL
of	NULL
inducibility/cell	NULL
type	NULL
specificity	NULL
.	NULL

Regulatory	NULL
regions	NULL
for	NULL
eukaryotic	NULL
RNA	NULL
polymerase	NULL
II	NULL
transcription	NULL
units	NULL
are	NULL
located	NULL
both	NULL
upstream	NULL
and	NULL
downstream	NULL
of	NULL
the	NULL
RNA	NULL
start	NULL
site	NULL
and	NULL
are	NULL
usually	NULL
defined	NULL
as	NULL
(	NULL
proximal	NULL
)	NULL
promoters	NULL
and	NULL
(	NULL
remote	NULL
)	NULL
enhancers	NULL
.	NULL

The	NULL
difference	NULL
between	NULL
an	NULL
enhancer	NULL
and	NULL
a	NULL
promoter	NULL
is	NULL
largely	NULL
operational	NULL
,	NULL
since	NULL
both	NULL
are	NULL
composed	NULL
of	NULL
a	NULL
number	NULL
of	NULL
short	NULL
DNA	NULL
sequence	NULL
motifs	NULL
that	NULL
serve	NULL
as	NULL
recognition	NULL
sequences	NULL
for	NULL
transcription	NULL
fac-tors	NULL
.	NULL

Enhancers	NULL
can	NULL
act	NULL
in	NULL
either	NULL
orientation	NULL
and	NULL
over	NULL
long	NULL
distances	NULL
,	NULL
whether	NULL
tested	NULL
on	NULL
homologous	NULL
or	NULL
heterologous	NULL
promoters	NULL
(	NULL
reviewed	NULL
in	NULL
Serfling	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
)	NULL
.	NULL

Some	NULL
of	NULL
these	NULL
cis-acting	NULL
DNA	NULL
sequence	NULL
motifs	NULL
(	NULL
=	NULL
modules	NULL
,	NULL
elements	NULL
)	NULL
are	NULL
preferentially	NULL
found	NULL
in	NULL
either	NULL
a	NULL
promoter	NULL
or	NULL
an	NULL
enhancer	NULL
position	NULL
,	NULL
whereas	NULL
others	NULL
,	NULL
like	NULL
the	NULL
octamer	NULL
motif	NULL
,	NULL
can	NULL
be	NULL
found	NULL
in	NULL
close	NULL
proximity	NULL
to	NULL
the	NULL
transcriptional	NULL
start	NULL
site	NULL
as	NULL
well	NULL
as	NULL
at	NULL
remote	NULL
positions	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
a	NULL
particular	NULL
cis-acting	NULL
element	NULL
varies	NULL
between	NULL
different	NULL
cell	NULL
types	NULL
.	NULL

The	NULL
general	NULL
picture	NULL
emerging	NULL
from	NULL
studies	NULL
in	NULL
several	NULL
laboratories	NULL
is	NULL
that	NULL
the	NULL
concentration	NULL
of	NULL
the	NULL
active	NULL
form	NULL
of	NULL
a	NULL
transcription	NULL
factor	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
number	NULL
and	NULL
affinity	NULL
of	NULL
corresponding	NULL
binding	NULL
sites	NULL
on	NULL
the	NULL
DNA	NULL
,	NULL
influence	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
(	NULL
for	NULL
reviews	NULL
,	NULL
see	NULL
Maniatis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Miiller	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988a	NULL
;	NULL
Mitchell	NULL
and	NULL
Tjian	NULL
,	NULL
1989	NULL
;	NULL
Johnson	NULL
and	NULL
McKnight	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

In	NULL
principle	NULL
,	NULL
a	NULL
single	NULL
binding	NULL
site	NULL
in	NULL
conjunction	NULL
with	NULL
a	NULL
corresponding	NULL
transcription	NULL
factor	NULL
can	NULL
be	NULL
subject	NULL
to	NULL
cell	NULL
type-specific	NULL
(	NULL
or	NULL
in-ducible	NULL
)	NULL
regulation	NULL
(	NULL
Dreyfus	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Wirth	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Gerster	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

The	NULL
interplay	NULL
between	NULL
the	NULL
various	NULL
factors	NULL
is	NULL
as	NULL
yet	NULL
poorly	NULL
understood	NULL
,	NULL
but	NULL
it	NULL
influences	NULL
gene	NULL
activity	NULL
as	NULL
well	NULL
(	NULL
see	NULL
,	NULL
for	NULL
example	NULL
,	NULL
Hu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Murre	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Schatt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
for	NULL
reviews	NULL
see	NULL
Mitchell	NULL
and	NULL
Tjian	NULL
,	NULL
1989	NULL
;	NULL
Johnson	NULL
and	NULL
Received	NULL
December	NULL
17	NULL
,	NULL
1990	NULL
;	NULL
revision	NULL
accepted	NULL
January	NULL
15	NULL
,	NULL
1991	NULL
.	NULL

Correspondence	NULL
:	NULL
Walter	NULL
Schaffner	NULL
,	NULL
Institute	NULL
for	NULL
Molecular	NULL
Biology	NULL
II	NULL
,	NULL
University	NULL
of	NULL
Ziirich	NULL
,	NULL
Honggerberg	NULL
CH-8093	NULL
Zurich	NULL
,	NULL
Switzerland	NULL
-	NULL
Tel	NULL
41-1-377-34-07	NULL
and	NULL
377-34-48	NULL
-	NULL
Fax	NULL
4111-371-48-73	NULL
Â©	NULL
1991	NULL
by	NULL
the	NULL
University	NULL
of	NULL
Health	NULL
Sciences/The	NULL
Chicago	NULL
Medical	NULL
School	NULL
.	NULL

All	NULL
rights	NULL
reserved	NULL
.	NULL

1052-2166/91/10101/071-11	NULL
$	NULL
2.00	NULL
71	NULL
72	NULL
McKnight	NULL
,	NULL
1989	NULL
;	NULL
Abel	NULL
and	NULL
Maniatis	NULL
,	NULL
1990	NULL
;	NULL
Jones	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

The	NULL
enhancer	NULL
of	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
(	NULL
IgH	NULL
)	NULL
genes	NULL
was	NULL
the	NULL
first	NULL
example	NULL
found	NULL
of	NULL
an	NULL
enhancer	NULL
associated	NULL
with	NULL
a	NULL
cellular	NULL
gene	NULL
,	NULL
and	NULL
also	NULL
the	NULL
first	NULL
component	NULL
identified	NULL
in	NULL
the	NULL
then	NULL
enigmatic	NULL
phenomenon	NULL
of	NULL
cell	NULL
type-specific	NULL
gene	NULL
expression	NULL
(	NULL
Banerji	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1983	NULL
;	NULL
Gillies	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1983	NULL
,	NULL
Neuberger	NULL
,	NULL
1983	NULL
)	NULL
.	NULL

The	NULL
IgH	NULL
enhancer	NULL
shows	NULL
a	NULL
strict	NULL
cell	NULL
type	NULL
specificity	NULL
:	NULL
it	NULL
is	NULL
active	NULL
in	NULL
B	NULL
lymphocytes	NULL
but	NULL
not	NULL
,	NULL
for	NULL
example	NULL
,	NULL
in	NULL
epi-thelial	NULL
or	NULL
fibroblast	NULL
cells	NULL
.	NULL

Subsequently	NULL
,	NULL
it	NULL
was	NULL
found	NULL
that	NULL
not	NULL
only	NULL
the	NULL
Ig	NULL
enhancers	NULL
but	NULL
also	NULL
the	NULL
promoters	NULL
of	NULL
Ig	NULL
heavy	NULL
and	NULL
light	NULL
chain	NULL
genes	NULL
are	NULL
preferentially	NULL
active	NULL
in	NULL
lymphoid	NULL
cells	NULL
(	NULL
Falk-ner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
;	NULL
Picard	NULL
and	NULL
Schaffner	NULL
,	NULL
1985	NULL
;	NULL
Mason	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Grosschedl	NULL
and	NULL
Baltimore	NULL
,	NULL
1985	NULL
;	NULL
Foster	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Mizushima-Sugano	NULL
and	NULL
Roeder	NULL
,	NULL
1986	NULL
)	NULL
.	NULL

It	NULL
is	NULL
well-established	NULL
that	NULL
a	NULL
functional	NULL
enhancer	NULL
and	NULL
a	NULL
promoter	NULL
act	NULL
synergistically	NULL
to	NULL
bring	NULL
about	NULL
strong	NULL
transcription	NULL
.	NULL

There	NULL
are	NULL
also	NULL
reports	NULL
that	NULL
there	NULL
is	NULL
an	NULL
additional	NULL
level	NULL
of	NULL
specificity	NULL
to	NULL
this	NULL
enhancer-promoter	NULL
interaction	NULL
.	NULL

For	NULL
example	NULL
,	NULL
Garcia	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
have	NULL
proposed	NULL
that	NULL
the	NULL
cell	NULL
type-specific	NULL
immunoglobulin	NULL
gene	NULL
enhancers	NULL
are	NULL
preferentially	NULL
active	NULL
in	NULL
combination	NULL
with	NULL
their	NULL
own	NULL
promoters	NULL
.	NULL

Such	NULL
preferences	NULL
could	NULL
have	NULL
been	NULL
the	NULL
result	NULL
of	NULL
coevolution	NULL
of	NULL
an	NULL
enhancer	NULL
and	NULL
its	NULL
corresponding	NULL
promoter	NULL
.	NULL

We	NULL
have	NULL
addressed	NULL
the	NULL
question	NULL
of	NULL
preferential	NULL
activity	NULL
by	NULL
analyzing	NULL
the	NULL
functional	NULL
cooperation	NULL
between	NULL
given	NULL
promoter	NULL
and	NULL
enhancer	NULL
sequences	NULL
with	NULL
a	NULL
number	NULL
of	NULL
construc-tions	NULL
.	NULL

We	NULL
wanted	NULL
to	NULL
determine	NULL
whether	NULL
it	NULL
was	NULL
possible	NULL
,	NULL
for	NULL
example	NULL
,	NULL
to	NULL
create	NULL
a	NULL
particularly	NULL
strong	NULL
transcription	NULL
unit	NULL
by	NULL
having	NULL
the	NULL
same	NULL
DNA	NULL
motif	NULL
act	NULL
from	NULL
both	NULL
an	NULL
upstream	NULL
and	NULL
a	NULL
downstream	NULL
position	NULL
.	NULL

The	NULL
results	NULL
presented	NULL
in	NULL
this	NULL
paper	NULL
,	NULL
which	NULL
were	NULL
obtained	NULL
by	NULL
measuring	NULL
expression	NULL
of	NULL
transiently	NULL
transfected	NULL
cell	NULL
lines	NULL
,	NULL
do	NULL
not	NULL
indicate	NULL
a	NULL
marked	NULL
preference	NULL
for	NULL
a	NULL
par	NULL
Kermekchiev	NULL
et	NULL
al	NULL
.	NULL

ticular	NULL
enhancer/promoter	NULL
combination	NULL
.	NULL

Rather	NULL
,	NULL
different	NULL
promoters	NULL
were	NULL
always	NULL
activated	NULL
to	NULL
about	NULL
the	NULL
same	NULL
relative	NULL
level	NULL
by	NULL
the	NULL
various	NULL
enhancers	NULL
tested	NULL
.	NULL

This	NULL
ability	NULL
to	NULL
combine	NULL
various	NULL
enhancers	NULL
and	NULL
promoters	NULL
may	NULL
have	NULL
facilitated	NULL
the	NULL
evolution	NULL
of	NULL
new	NULL
regulatory	NULL
pathways	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Construction	NULL
of	NULL
plasmids	NULL
All	NULL
clones	NULL
were	NULL
constructed	NULL
according	NULL
to	NULL
standard	NULL
recombinant	NULL
DNA	NULL
protocols	NULL
(	NULL
Maniatis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
.	NULL

The	NULL
plasmid	NULL
constructs	NULL
containing	NULL
the	NULL
Ig	NULL
kappa-promoter	NULL
and	NULL
its	NULL
derivatives	NULL
are	NULL
based	NULL
on	NULL
the	NULL
pK	NULL
plasmid	NULL
(	NULL
Picard	NULL
and	NULL
Schaffner	NULL
,	NULL
1985	NULL
)	NULL
in	NULL
which	NULL
different	NULL
promoter	NULL
and	NULL
enhancer	NULL
elements	NULL
were	NULL
placed	NULL
upstream	NULL
and	NULL
downstream	NULL
,	NULL
respectively	NULL
,	NULL
of	NULL
a	NULL
truncated	NULL
B-globin	NULL
gene	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

In	NULL
the	NULL
KapP	NULL
series	NULL
a	NULL
promoter	NULL
fragment	NULL
(	NULL
Ddel-Hinfl	NULL
)	NULL
from	NULL
a	NULL
mouse	NULL
x-light	NULL
chain	NULL
gene	NULL
,	NULL
including	NULL
the	NULL
octamer	NULL
and	NULL
TATA	NULL
box	NULL
sequences	NULL
as	NULL
well	NULL
as	NULL
the	NULL
cap	NULL
site	NULL
(	NULL
nucleotides	NULL
-	NULL
180	NULL
to	NULL
+22	NULL
)	NULL
was	NULL
fused	NULL
to	NULL
the	NULL
B-globin	NULL
reporter	NULL
gene	NULL
.	NULL

In	NULL
the	NULL
two	NULL
promoter	NULL
variants	NULL
Kap	NULL
(	NULL
-	NULL
)	NULL
P	NULL
and	NULL
SpIlP	NULL
,	NULL
the	NULL
octamer	NULL
motif	NULL
of	NULL
the	NULL
promoter	NULL
was	NULL
replaced	NULL
by	NULL
its	NULL
mutated	NULL
variant	NULL
or	NULL
by	NULL
the	NULL
binding	NULL
site	NULL
for	NULL
Spl	NULL
,	NULL
respectively	NULL
,	NULL
preserving	NULL
the	NULL
original	NULL
TATA	NULL
box	NULL
.	NULL

To	NULL
this	NULL
end	NULL
,	NULL
a	NULL
52	NULL
bp	NULL
Pvull-StyI	NULL
fragment	NULL
in	NULL
KapP	NULL
was	NULL
replaced	NULL
by	NULL
synthetic	NULL
se-quences	NULL
,	NULL
as	NULL
shown	NULL
below	NULL
:	NULL
KapP	NULL
wild	NULL
type	NULL
octamer	NULL
_	NULL
5	NULL
ATTTGCAT	NULL
TAAACGTA	NULL
5	NULL
Kap	NULL
(	NULL
-	NULL
)	NULL
P	NULL
_	NULL
mutated	NULL
octamer	NULL
5	NULL
ATGTTCAG	NULL
TACAAGTC	NULL
5	NULL
SpIP	NULL
Spl	NULL
binding	NULL
site	NULL
5	NULL
GGGCGGGGC	NULL
(	NULL
HSV	NULL
)	NULL
CCCGCCCCG	NULL
5	NULL
The	NULL
enhancer	NULL
elements	NULL
were	NULL
inserted	NULL
downstream	NULL
of	NULL
the	NULL
test	NULL
gene	NULL
:	NULL
IgLE	NULL
,	NULL
a	NULL
480	NULL
bp	NULL
Alul	NULL
frag-	NULL
Figure	NULL
1	NULL
.	NULL

Schematic	NULL
representation	NULL
of	NULL
the	NULL
recombinant	NULL
DNAs	NULL
.	NULL

-	NULL
A.	NULL
DNA	NULL
constructs	NULL
with	NULL
the	NULL
immunoglobulin	NULL
kappa	NULL
light	NULL
chain	NULL
promoter	NULL
and	NULL
its	NULL
derivatives	NULL
.	NULL

A	NULL
202	NULL
bp	NULL
fragment	NULL
of	NULL
a	NULL
mouse	NULL
x	NULL
chain	NULL
promoter	NULL
or	NULL
its	NULL
derivatives	NULL
(	NULL
black	NULL
region	NULL
)	NULL
was	NULL
fused	NULL
to	NULL
a	NULL
truncated	NULL
rabbit	NULL
B-globin	NULL
gene	NULL
(	NULL
white	NULL
region	NULL
)	NULL
.	NULL

Promoter	NULL
and	NULL
enhancer	NULL
sequences	NULL
used	NULL
in	NULL
these	NULL
constructs	NULL
are	NULL
designated	NULL
with	NULL
the	NULL
letters	NULL
P	NULL
and	NULL
E	NULL
,	NULL
respectively	NULL
.	NULL

Plasmid	NULL
DNA	NULL
is	NULL
shown	NULL
by	NULL
a	NULL
wavy	NULL
line	NULL
.	NULL

The	NULL
constructions	NULL
are	NULL
not	NULL
drawn	NULL
to	NULL
scale	NULL
.	NULL

B.	NULL
DNA	NULL
constructs	NULL
with	NULL
the	NULL
SV40	NULL
promoter	NULL
.	NULL

The	NULL
21	NULL
bp	NULL
repeats	NULL
from	NULL
the	NULL
early	NULL
promoter	NULL
region	NULL
of	NULL
SV40	NULL
containing	NULL
5	NULL
functional	NULL
Spl	NULL
binding	NULL
sites	NULL
(	NULL
stippled	NULL
boxes	NULL
)	NULL
were	NULL
placed	NULL
in	NULL
front	NULL
of	NULL
the	NULL
B-globin	NULL
gene	NULL
(	NULL
white	NULL
region	NULL
)	NULL
.	NULL

The	NULL
enhancers	NULL
used	NULL
are	NULL
identical	NULL
to	NULL
some	NULL
of	NULL
those	NULL
shown	NULL
in	NULL
A.	NULL
C.	NULL
DNA	NULL
constructs	NULL
containing	NULL
the	NULL
OVEC	NULL
reporter	NULL
gene	NULL
.	NULL

OVEC	NULL
is	NULL
a	NULL
reporter	NULL
gene	NULL
containing	NULL
the	NULL
coding	NULL
sequence	NULL
of	NULL
the	NULL
rabbit	NULL
B-globin	NULL
gene	NULL
(	NULL
as	NULL
are	NULL
the	NULL
constructs	NULL
in	NULL
A	NULL
and	NULL
B	NULL
)	NULL
and	NULL
convenient	NULL
cloning	NULL
sites	NULL
for	NULL
promoter	NULL
and	NULL
enhancer	NULL
elements	NULL
(	NULL
Westin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

DNA	NULL
oligonucleotides	NULL
containing	NULL
a	NULL
single	NULL
or	NULL
a	NULL
duplicated	NULL
binding	NULL
site	NULL
for	NULL
different	NULL
transcription	NULL
factors	NULL
were	NULL
inserted	NULL
upstream	NULL
of	NULL
the	NULL
B-globin	NULL
TATA	NULL
box	NULL
(	NULL
white	NULL
)	NULL
.	NULL

These	NULL
promoter	NULL
constructions	NULL
were	NULL
tested	NULL
with	NULL
the	NULL
SV40	NULL
enhancer	NULL
or	NULL
a	NULL
multimeric	NULL
NF-xB	NULL
enhancer	NULL
.	NULL

No	NULL
evidence	NULL
for	NULL
enhancer/promoter	NULL
preference	NULL
73	NULL
A	NULL
$	NULL
9	NULL
â¬Â®mm	NULL
p-	NULL
Â»	NULL
_	NULL
Bglobin	NULL
Promoter	NULL
Enhancer	NULL
designation	NULL
:	NULL
octamer	NULL
,	NULL
.	NULL

designation	NULL
:	NULL
KapP	NULL
r-light	NULL
chain	NULL
IgLE	NULL
mutant	NULL
octamer	NULL
he	NULL
avy	NULL
chain	NULL
Kap	NULL
``	NULL
P	NULL
â|X|â	NULL
IgHE	NULL
Spl	NULL
SpiP__-	NULL
--	NULL
-	NULL
_-_	NULL
SVE	NULL
MoMSV	NULL
MSVE	NULL
6xE4/octamer	NULL
EFA0OcE	NULL
6xE4	NULL
``	NULL
/octamer	NULL
E4	NULL
``	NULL
OcE	NULL
B	NULL
Spl	NULL
sites	NULL
TATA	NULL
p-	NULL
Â»	NULL
Bâglobln	NULL
SVP	NULL
IgLE	NULL
IgHE	NULL
SVE	NULL
C	NULL
TATA	NULL
-	NULL
[	NULL
~*	NULL
-globin	NULL
AAR	NULL
_-	NULL
}	NULL
[	NULL
_	NULL
}	NULL
Promoter	NULL
Enhancer	NULL
designation	NULL
:	NULL
designation	NULL
:	NULL
SV40	NULL
OctP	NULL
-R-	NULL
SVE	NULL
NF	NULL
â	NULL
KBP	NULL
8XNF'KB	NULL
Site	NULL
t	NULL
aome	NULL
NF-	NULL
Â«	NULL
BE	NULL
PuP	NULL
25pIP	NULL
-E-	NULL
74	NULL
ment	NULL
derived	NULL
from	NULL
the	NULL
mouse	NULL
x-light	NULL
chain	NULL
enhancer	NULL
(	NULL
Picard	NULL
and	NULL
Schaffner	NULL
,	NULL
1984	NULL
)	NULL
;	NULL
IgHE	NULL
,	NULL
a	NULL
690	NULL
bp	NULL
XbaI-EcoRI	NULL
fragment	NULL
from	NULL
the	NULL
mouse	NULL
heavy	NULL
chain	NULL
enhancer	NULL
(	NULL
Banerji	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1983	NULL
)	NULL
;	NULL
SV40E	NULL
,	NULL
a	NULL
200	NULL
bp	NULL
segment	NULL
including	NULL
the	NULL
two	NULL
72	NULL
bp	NULL
repeats	NULL
of	NULL
the	NULL
SV40	NULL
enhancer	NULL
(	NULL
Banerji	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1981	NULL
)	NULL
;	NULL
MSVE	NULL
,	NULL
a	NULL
350	NULL
bp	NULL
Bam	NULL
HI	NULL
fragment	NULL
from	NULL
the	NULL
Moloney	NULL
sarcoma	NULL
virus	NULL
LTR	NULL
(	NULL
Levinson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
.	NULL

The	NULL
synthetic	NULL
enhancers	NULL
used	NULL
in	NULL
the	NULL
plasmid	NULL
series	NULL
,	NULL
E4	NULL
OcE	NULL
and	NULL
E4	NULL
(	NULL
-	NULL
)	NULL
OcEF	NULL
,	NULL
consist	NULL
of	NULL
six	NULL
repeated	NULL
51	NULL
bp	NULL
fragments	NULL
from	NULL
the	NULL
IgH	NULL
enhancer	NULL
,	NULL
each	NULL
consisting	NULL
of	NULL
the	NULL
octamer	NULL
sequence	NULL
plus	NULL
a	NULL
functional	NULL
or	NULL
mutated	NULL
E4	NULL
motif	NULL
,	NULL
respectively	NULL
(	NULL
Gerster	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

The	NULL
reference	NULL
plasmid	NULL
REF	NULL
was	NULL
described	NULL
previously	NULL
(	NULL
Picard	NULL
and	NULL
Schaffner	NULL
,	NULL
1985	NULL
)	NULL
.	NULL

The	NULL
SVP	NULL
constructs	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
contain	NULL
an	NULL
SV40	NULL
fragment	NULL
consisting	NULL
of	NULL
the	NULL
three	NULL
21	NULL
bp	NULL
early	NULL
promoter	NULL
repeats	NULL
(	NULL
five	NULL
Spl	NULL
binding	NULL
sites	NULL
)	NULL
,	NULL
was	NULL
placed	NULL
in	NULL
front	NULL
of	NULL
the	NULL
TATA	NULL
box	NULL
of	NULL
the	NULL
B-globin	NULL
gene	NULL
,	NULL
whose	NULL
first	NULL
intron	NULL
in	NULL
this	NULL
case	NULL
was	NULL
preserved	NULL
.	NULL

The	NULL
two	NULL
plasmids	NULL
containing	NULL
the	NULL
rabbit	NULL
f-globin	NULL
promoter	NULL
are	NULL
described	NULL
in	NULL
Gerster	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
.	NULL

The	NULL
OVEC	NULL
system	NULL
(	NULL
Westin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
was	NULL
employed	NULL
to	NULL
construct	NULL
the	NULL
series	NULL
of	NULL
plasmids	NULL
containing	NULL
single	NULL
transcription	NULL
factor	NULL
binding	NULL
sites	NULL
.	NULL

Oligonucleotides	NULL
with	NULL
the	NULL
octamer	NULL
(	NULL
oct	NULL
)	NULL
or	NULL
NF-	NULL
Â«	NULL
xB	NULL
binding	NULL
sites	NULL
or	NULL
the	NULL
Pu	NULL
box	NULL
(	NULL
Pu	NULL
)	NULL
were	NULL
synthesized	NULL
with	NULL
Sacl	NULL
and	NULL
Sall	NULL
protruding	NULL
ends	NULL
and	NULL
inserted	NULL
in	NULL
front	NULL
of	NULL
the	NULL
TATA	NULL
box	NULL
.	NULL

The	NULL
Spl	NULL
oligonucleotide	NULL
(	NULL
2	NULL
Spl	NULL
)	NULL
contains	NULL
a	NULL
dimer	NULL
of	NULL
a	NULL
binding	NULL
site	NULL
found	NULL
in	NULL
the	NULL
immediate	NULL
early	NULL
gene	NULL
3	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
.	NULL

It	NULL
was	NULL
synthesized	NULL
with	NULL
blunt	NULL
ends	NULL
and	NULL
ligated	NULL
into	NULL
the	NULL
Sall	NULL
site	NULL
,	NULL
which	NULL
was	NULL
filled	NULL
in	NULL
by	NULL
T4	NULL
polymerase	NULL
.	NULL

The	NULL
sequences	NULL
of	NULL
the	NULL
oligonucleotides	NULL
are	NULL
shown	NULL
in	NULL
Table	NULL
1	NULL
.	NULL

The	NULL
reference	NULL
plasmid	NULL
used	NULL
for	NULL
this	NULL
series	NULL
of	NULL
plasmids	NULL
was	NULL
OVEC-REF	NULL
(	NULL
Westin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

Table	NULL
1	NULL
.	NULL

Sequences	NULL
of	NULL
oligonucleotides	NULL
.	NULL

Kermekchiev	NULL
et	NULL
al	NULL
.	NULL

Cell	NULL
growth	NULL
,	NULL
transfection	NULL
,	NULL
and	NULL
RNA	NULL
analysis	NULL
The	NULL
human	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
BJA-B	NULL
and	NULL
the	NULL
myeloma	NULL
cells	NULL
X63Ag8	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
and	NULL
DMEM	NULL
media	NULL
,	NULL
respectively	NULL
.	NULL

Both	NULL
media	NULL
were	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
100	NULL
U/ml	NULL
penicillin	NULL
and	NULL
100	NULL
ug/ml	NULL
streptomy-cin	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
5	NULL
or	NULL
10	NULL
ug	NULL
test	NULL
plasmid	NULL
and	NULL
2	NULL
ug	NULL
reference	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
procedure	NULL
followed	NULL
by	NULL
a	NULL
DMSO	NULL
boost	NULL
.	NULL

Cytoplasmic	NULL
RNA	NULL
was	NULL
isolated	NULL
40-42	NULL
hr	NULL
after	NULL
transfection	NULL
and	NULL
purified	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
De	NULL
Villiers	NULL
and	NULL
Schaffner	NULL
,	NULL
1983	NULL
)	NULL
.	NULL

The	NULL
specific	NULL
transcripts	NULL
were	NULL
quantitated	NULL
by	NULL
ribonuclease	NULL
mapping	NULL
(	NULL
Melton	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
,	NULL
with	NULL
some	NULL
modifications	NULL
,	NULL
see	NULL
Picard	NULL
and	NULL
Schaffner	NULL
,	NULL
1985	NULL
)	NULL
or	NULL
S1	NULL
nuclease	NULL
analysis	NULL
(	NULL
de	NULL
Villiers	NULL
and	NULL
Schaffner	NULL
,	NULL
1983	NULL
)	NULL
.	NULL

For	NULL
S1	NULL
nuclease	NULL
analysis	NULL
of	NULL
the	NULL
transcripts	NULL
from	NULL
the	NULL
KapP	NULL
constructs	NULL
and	NULL
their	NULL
derivatives	NULL
,	NULL
as	NULL
well	NULL
as	NULL
for	NULL
the	NULL
SVP	NULL
constructs	NULL
,	NULL
a	NULL
BamHI-labeled	NULL
Sacl-BamHI	NULL
fragment	NULL
(	NULL
nucleotides	NULL
-195	NULL
to	NULL
+215	NULL
)	NULL
was	NULL
used	NULL
as	NULL
probe	NULL
.	NULL

The	NULL
reverse	NULL
SP6	NULL
polymerase	NULL
transcript	NULL
of	NULL
the	NULL
same	NULL
fragment	NULL
was	NULL
used	NULL
for	NULL
ribonuclease	NULL
mapping	NULL
(	NULL
Picard	NULL
and	NULL
Schaffner	NULL
,	NULL
1985	NULL
)	NULL
.	NULL

Results	NULL
Transcriptional	NULL
activation	NULL
of	NULL
the	NULL
Ig	NULL
kappa	NULL
promoter	NULL
by	NULL
different	NULL
enhancers	NULL
in	NULL
B	NULL
cells	NULL
We	NULL
have	NULL
tested	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
B-globin	NULL
reporter	NULL
gene	NULL
driven	NULL
by	NULL
an	NULL
immunoglobulin	NULL
kappa	NULL
gene	NULL
promoter	NULL
in	NULL
B-type	NULL
lymphoid	NULL
cells	NULL
(	NULL
BJA-B	NULL
;	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

The	NULL
reporter	NULL
gene	NULL
,	NULL
together	NULL
with	NULL
a	NULL
reference	NULL
gene	NULL
as	NULL
a	NULL
standard	NULL
for	NULL
transfection	NULL
effi-ciency	NULL
,	NULL
was	NULL
transfected	NULL
into	NULL
these	NULL
cells	NULL
by	NULL
the	NULL
DEAE	NULL
dextran	NULL
method	NULL
.	NULL

After	NULL
40-42	NULL
hr	NULL
specific	NULL
transcripts	NULL
from	NULL
the	NULL
kappa	NULL
promoter	NULL
were	NULL
analyzed	NULL
by	NULL
S1	NULL
nuclease	NULL
or	NULL
ribonuclease	NULL
mapping	NULL
.	NULL

The	NULL
gene	NULL
was	NULL
either	NULL
expressed	NULL
without	NULL
en-	NULL
Oct	NULL
:	NULL
5	NULL
'	NULL
CGAGCCCGGGGTAATTTGCATTTCTACTAG	NULL
TCGAGCTCGGGCCCCATTAAACGTAAAGATGATCAGCT	NULL
5	NULL
NF-xB	NULL
:	NULL
_	NULL
5	NULL
CGAGAACAGAGGGGACTTTCCGAGAGCGCC	NULL
TCGAGCTCTTGTCTCCCCTGAAAGGCTCTCCGGCAGCT	NULL
5	NULL
Pu	NULL
:	NULL
5	NULL
'	NULL
CGAGAGTTCCTCTTTCAGAG	NULL
TCGAGCTCTCAAGGAGAAAGTCTCAGCT	NULL
5	NULL
2Sp1	NULL
:	NULL
0	NULL
5	NULL
CCGGCCCCGCCcCcaTccccGGccccacccatTcC	NULL
GGCCGGGGCGGGTAGGGGCCGGGGCGGCGTAGCG	NULL
5	NULL
No	NULL
evidence	NULL
for	NULL
enhancer/promoter	NULL
preference	NULL
A	NULL
x-promoter	NULL
B	NULL
ct	NULL
SV40-promoter	NULL
75	NULL
Figure	NULL
2	NULL
.	NULL

Transcriptional	NULL
activation	NULL
of	NULL
two	NULL
genuine	NULL
promoters	NULL
by	NULL
different	NULL
enhancers	NULL
.	NULL

A.	NULL
Sl	NULL
nucle-C	NULL
C	NULL
ase	NULL
analysis	NULL
of	NULL
Igx	NULL
promoter	NULL
activ-	NULL
ity	NULL
.	NULL

Human	NULL
B-type	NULL
lymphoblastoid	NULL
cells	NULL
(	NULL
BJA-B	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
seven	NULL
constructs	NULL
including	NULL
the	NULL
x-light	NULL
chain	NULL
promoter	NULL
alone	NULL
(	NULL
desig-nated	NULL
``	NULL
0	NULL
,	NULL
``	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
the	NULL
six	NULL
enhancers	NULL
shown	NULL
in	NULL
Figure	NULL
1A	NULL
(	NULL
lanes	NULL
2-7	NULL
,	NULL
designation	NULL
according	NULL
to	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

The	NULL
products	NULL
of	NULL
S1	NULL
nuclease	NULL
protection	NULL
were	NULL
analyzed	NULL
on	NULL
a	NULL
denaturing	NULL
6	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
parallel	NULL
with	NULL
size	NULL
markers	NULL
(	NULL
M	NULL
)	NULL
of	NULL
Hpall	NULL
digested	NULL
6	NULL
pBR322	NULL
DNA	NULL
.	NULL

The	NULL
bands	NULL
corresponding	NULL
to	NULL
the	NULL
correctly	NULL
initiated	NULL
and	NULL
the	NULL
reference	NULL
transcripts	NULL
are	NULL
indicated	NULL
with	NULL
``	NULL
ct	NULL
``	NULL
and	NULL
``	NULL
ref	NULL
,	NULL
``	NULL
respectively	NULL
.	NULL

B	NULL
.	NULL

Activity	NULL
of	NULL
the	NULL
SV40	NULL
promoter	NULL
.	NULL

The	NULL
same	NULL
proce-	NULL
dure	NULL
as	NULL
in	NULL
A	NULL
was	NULL
used	NULL
for	NULL
transcriptional	NULL
analysis	NULL
of	NULL
the	NULL
SV40	NULL
promoter	NULL
constructs	NULL
depicted	NULL
in	NULL
B	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
this	NULL
promoter	NULL
by	NULL
the	NULL
IgH	NULL
(	NULL
heavy	NULL
)	NULL
-	NULL
and	NULL
IgL	NULL
(	NULL
x	NULL
)	NULL
-enhancers	NULL
is	NULL
shown	NULL
in	NULL
lanes	NULL
3	NULL
,	NULL
4	NULL
and	NULL
5	NULL
,	NULL
respectively	NULL
.	NULL

``	NULL
0	NULL
,	NULL
``	NULL
SV40	NULL
promoter	NULL
construct	NULL
without	NULL
enhancer	NULL
.	NULL

All	NULL
other	NULL
designations	NULL
are	NULL
as	NULL
in	NULL
A.	NULL
hancer	NULL
,	NULL
or	NULL
with	NULL
one	NULL
of	NULL
the	NULL
following	NULL
six	NULL
enhance-ers	NULL
:	NULL
1	NULL
.	NULL

The	NULL
homologous	NULL
immunoglobulin	NULL
kappa	NULL
enhancer	NULL
located	NULL
within	NULL
the	NULL
J/C	NULL
intron	NULL
(	NULL
Queen	NULL
and	NULL
Baltimore	NULL
,	NULL
1983	NULL
;	NULL
Picard	NULL
and	NULL
Schaffner	NULL
,	NULL
1984	NULL
)	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
tested	NULL
this	NULL
enhancer	NULL
with	NULL
the	NULL
B-globin	NULL
promoter	NULL
and	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
,	NULL
where	NULL
it	NULL
shows	NULL
only	NULL
about	NULL
5	NULL
%	NULL
of	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
strong	NULL
enhancer	NULL
from	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
genes	NULL
(	NULL
Picard	NULL
and	NULL
Schaffner	NULL
,	NULL
1984	NULL
)	NULL
.	NULL

Others	NULL
have	NULL
reported	NULL
that	NULL
a	NULL
preferential	NULL
interaction	NULL
between	NULL
the	NULL
kappa	NULL
enhancer	NULL
and	NULL
kappa	NULL
promoter	NULL
results	NULL
in	NULL
a	NULL
transcriptional	NULL
efficiency	NULL
approaching	NULL
that	NULL
seen	NULL
with	NULL
strong	NULL
enhancers	NULL
(	NULL
Garcia	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

2	NULL
.	NULL

The	NULL
IgH	NULL
enhancer	NULL
,	NULL
which	NULL
is	NULL
also	NULL
B	NULL
cell-specific	NULL
,	NULL
as	NULL
mentioned	NULL
above	NULL
(	NULL
Banerji	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1983	NULL
;	NULL
Gillies	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1983	NULL
;	NULL
Neuberger	NULL
,	NULL
1983	NULL
)	NULL
.	NULL

3	NULL
.	NULL

The	NULL
SV40	NULL
enhancer	NULL
,	NULL
the	NULL
first	NULL
described	NULL
and	NULL
thoroughly	NULL
characterized	NULL
enhancer	NULL
(	NULL
Banerji	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1981	NULL
;	NULL
Mor-eau	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1981	NULL
)	NULL
.	NULL

Under	NULL
natural	NULL
circumstances	NULL
,	NULL
it	NULL
drives	NULL
expression	NULL
from	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
that	NULL
contains	NULL
multiple	NULL
sites	NULL
for	NULL
the	NULL
transcription	NULL
factor	NULL
Spl	NULL
and	NULL
a	NULL
weak	NULL
TATA	NULL
box	NULL
(	NULL
Mathis	NULL
and	NULL
Chambon	NULL
,	NULL
1981	NULL
;	NULL
Benoist	NULL
and	NULL
Chambon	NULL
,	NULL
1981	NULL
;	NULL
Dynan	NULL
and	NULL
Tjian	NULL
,	NULL
1983	NULL
)	NULL
.	NULL

4	NULL
.	NULL

The	NULL
enhancer	NULL
from	NULL
the	NULL
Moloney	NULL
retrovirus	NULL
(	NULL
MSV	NULL
)	NULL
(	NULL
Levinson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1982	NULL
)	NULL
.	NULL

5	NULL
.	NULL

A	NULL
synthetic	NULL
enhancer	NULL
composed	NULL
of	NULL
6	NULL
identical	NULL
tandem	NULL
segments	NULL
of	NULL
50	NULL
bp	NULL
from	NULL
the	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
enhancer	NULL
,	NULL
containing	NULL
both	NULL
an	NULL
octamer	NULL
motif	NULL
and	NULL
an	NULL
Ephrussi	NULL
4	NULL
motif	NULL
(	NULL
Gerster	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

6	NULL
.	NULL

The	NULL
same	NULL
synthetic	NULL
enhancer	NULL
with	NULL
the	NULL
Ephrussi	NULL
4	NULL
motif	NULL
mutated	NULL
,	NULL
leaving	NULL
only	NULL
the	NULL
octamer	NULL
motif	NULL
intact	NULL
.	NULL

Both	NULL
synthetic	NULL
enhancers	NULL
retain	NULL
the	NULL
lymphocyte-specificity	NULL
of	NULL
the	NULL
complete	NULL
IgH	NULL
enhancer	NULL
(	NULL
Gerster	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

As	NULL
seen	NULL
in	NULL
Figure	NULL
2A	NULL
,	NULL
all	NULL
the	NULL
enhancers	NULL
tested	NULL
are	NULL
active	NULL
;	NULL
however	NULL
,	NULL
the	NULL
kappa	NULL
light	NULL
chain	NULL
enhancer	NULL
(	NULL
IgLE	NULL
)	NULL
is	NULL
only	NULL
about	NULL
10	NULL
%	NULL
as	NULL
active	NULL
as	NULL
the	NULL
heavy	NULL
chain	NULL
enhancer	NULL
and	NULL
only	NULL
5	NULL
%	NULL
as	NULL
active	NULL
as	NULL
the	NULL
SV40	NULL
enhancer	NULL
.	NULL

Similar	NULL
results	NULL
are	NULL
obtained	NULL
in	NULL
J-558	NULL
myeloma	NULL
cells	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
kappa	NULL
enhancer	NULL
,	NULL
which	NULL
is	NULL
known	NULL
to	NULL
be	NULL
weakly	NULL
active	NULL
with	NULL
non-homologous	NULL
promoters	NULL
,	NULL
does	NULL
not	NULL
perform	NULL
significantly	NULL
better	NULL
with	NULL
a	NULL
corresponding	NULL
kappa	NULL
promoter	NULL
.	NULL

A	NULL
possible	NULL
solution	NULL
to	NULL
the	NULL
paradox	NULL
of	NULL
the	NULL
low	NULL
activity	NULL
of	NULL
this	NULL
kappa	NULL
enhancer	NULL
has	NULL
recently	NULL
been	NULL
found	NULL
with	NULL
the	NULL
identification	NULL
of	NULL
a	NULL
second	NULL
enhancer	NULL
located	NULL
downstream	NULL
of	NULL
the	NULL
constant	NULL
region	NULL
of	NULL
the	NULL
kappa	NULL
gene	NULL
(	NULL
Meyer	NULL
and	NULL
Neuberger	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

The	NULL
same	NULL
order	NULL
of	NULL
relative	NULL
activity	NULL
is	NULL
also	NULL
observed	NULL
with	NULL
a	NULL
different	NULL
promoter	NULL
,	NULL
namely	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
,	NULL
whose	NULL
major	NULL
components	NULL
are	NULL
5	NULL
binding	NULL
sites	NULL
for	NULL
the	NULL
Spl	NULL
factor	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

76	NULL
Kermekchiev	NULL
et	NULL
al	NULL
.	NULL

C	NULL
Figure	NULL
3	NULL
.	NULL

Transcriptional	NULL
activa-	NULL
C	NULL
AV	NULL
C	NULL
C	NULL
Cj	NULL
tion	NULL
of	NULL
the	NULL
Igx	NULL
promoter	NULL
and	NULL
its	NULL
A	NULL
xS/XQ	NULL
â	NULL
VQ/	NULL
\	NULL
06	NULL
B	NULL
o	NULL
XÃ©	NULL
â	NULL
z	NULL
â	NULL
XÃ©	NULL
â	NULL
b	NULL
\	NULL
derivatives	NULL
by	NULL
different	NULL
enhancers	NULL
.	NULL

Q\	NULL
Q\	NULL
Â¢	NULL
Q\	NULL
Â§	NULL
\QQ\\Q	NULL
Q	NULL
'	NULL
Q	NULL
The	NULL
transcriptional	NULL
activity	NULL
of	NULL
four	NULL
fbâQ	NULL
3	NULL
be	NULL
be	NULL
PVP	NULL
P	NULL
series	NULL
of	NULL
constructs	NULL
including	NULL
the	NULL
/Â®/	NULL
%	NULL
/	NULL
%	NULL
Q/	NULL
$	NULL
t	NULL
(	NULL
sj	NULL
â	NULL
N/	NULL
â	NULL
E/g/	NULL
{	NULL
P	NULL
*	NULL
wild-type	NULL
promoter	NULL
(	NULL
KapP	NULL
)	NULL
and	NULL
its	NULL
derivatives	NULL
(	NULL
SpIP	NULL
or	NULL
Kap	NULL
(	NULL
-	NULL
)	NULL
P	NULL
,	NULL
see	NULL
1	NULL
]	NULL
g	NULL
I	NULL
?	NULL

A	NULL
:	NULL
If	NULL
;	NULL
T	NULL
g	NULL
1	NULL
?	NULL

A	NULL
:	NULL
if	NULL
)	NULL
Figure	NULL
1A	NULL
)	NULL
in	NULL
combination	NULL
with	NULL
tew	NULL
Shae	NULL
tine	NULL
ane	NULL
#	NULL
*	NULL
it	NULL
io	NULL
ug	NULL
tis	NULL
:	NULL
Lad	NULL
tow	NULL
lim	NULL
:	NULL
tre	NULL
A	NULL
promoter	NULL
with	NULL
an	NULL
Sp1	NULL
site	NULL
replacing	NULL
the	NULL
octamer	NULL
sequence	NULL
responds	NULL
to	NULL
the	NULL
various	NULL
enhancers	NULL
like	NULL
the	NULL
genuine	NULL
kappa	NULL
promoter	NULL
In	NULL
the	NULL
next	NULL
series	NULL
of	NULL
experiments	NULL
,	NULL
we	NULL
wanted	NULL
to	NULL
see	NULL
whether	NULL
a	NULL
given	NULL
upstream	NULL
factor	NULL
would	NULL
have	NULL
a	NULL
preference	NULL
for	NULL
a	NULL
particular	NULL
enhancer	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
kappa	NULL
promoter	NULL
,	NULL
we	NULL
also	NULL
tested	NULL
a	NULL
derivative	NULL
in	NULL
which	NULL
the	NULL
octamer	NULL
motif	NULL
was	NULL
replaced	NULL
by	NULL
consensus	NULL
binding	NULL
sites	NULL
for	NULL
Spl	NULL
factor	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

Both	NULL
the	NULL
kappa	NULL
promoter	NULL
and	NULL
the	NULL
Spl	NULL
promoter	NULL
were	NULL
tested	NULL
in	NULL
parallel	NULL
with	NULL
the	NULL
four	NULL
natural	NULL
enhancers	NULL
,	NULL
namely	NULL
the	NULL
Ig	NULL
kappa	NULL
light	NULL
and	NULL
heavy	NULL
chain	NULL
gene	NULL
enhancers	NULL
and	NULL
the	NULL
SV40	NULL
and	NULL
MSV	NULL
viral	NULL
enhancers	NULL
.	NULL

The	NULL
results	NULL
of	NULL
the	NULL
transfections	NULL
are	NULL
shown	NULL
in	NULL
Figure	NULL
3	NULL
.	NULL

As	NULL
is	NULL
evident	NULL
,	NULL
the	NULL
Spl-containing	NULL
promoter	NULL
is	NULL
weaker	NULL
ref	NULL
re	NULL
f	NULL
10	NULL
Â©	NULL
%	NULL
tiny	NULL
,	NULL
the	NULL
enhancers	NULL
from	NULL
IgL	NULL
(	NULL
x	NULL
)	NULL
(	NULL
A	NULL
)	NULL
;	NULL
IgH	NULL
(	NULL
heavy	NULL
chain	NULL
)	NULL
(	NULL
B	NULL
)	NULL
;	NULL
SV40	NULL
(	NULL
C	NULL
)	NULL
or	NULL
MoMSV	NULL
(	NULL
D	NULL
)	NULL
were	NULL
analyzed	NULL
by	NULL
S1	NULL
nuclease	NULL
mapping	NULL
.	NULL

The	NULL
construct	NULL
designations	NULL
are	NULL
according	NULL
to	NULL
Figure	NULL
1A	NULL
.	NULL

``	NULL
0	NULL
,	NULL
``	NULL
Igx	NULL
promoter	NULL
without	NULL
enhancer	NULL
.	NULL

All	NULL
other	NULL
designations	NULL
are	NULL
as	NULL
in	NULL
Figure	NULL
2	NULL
.	NULL

Mappings	NULL
shown	NULL
in	NULL
A	NULL
and	NULL
B	NULL
were	NULL
run	NULL
on	NULL
the	NULL
same	NULL
gel	NULL
along	NULL
with	NULL
the	NULL
same	NULL
size	NULL
marker	NULL
lane	NULL
.	NULL

The	NULL
bands	NULL
between	NULL
the	NULL
``	NULL
ref-	NULL
and	NULL
``	NULL
ct	NULL
``	NULL
bands	NULL
are	NULL
from	NULL
read-through	NULL
transcription	NULL
of	NULL
the	NULL
reference	NULL
plasmid	NULL
.	NULL

To	NULL
improve	NULL
presentation	NULL
of	NULL
the	NULL
data	NULL
,	NULL
different	NULL
G	NULL
autoradiogram	NULL
exposures	NULL
are	NULL
\Q	NULL
shown	NULL
for	NULL
A	NULL
and	NULL
B	NULL
,	NULL
and	NULL
the	NULL
size	NULL
0	NULL
marker	NULL
is	NULL
now	NULL
shown	NULL
at	NULL
the	NULL
sides	NULL
of	NULL
both	NULL
A	NULL
and	NULL
B.	NULL
than	NULL
the	NULL
kappa	NULL
promoter	NULL
in	NULL
the	NULL
BJA-B	NULL
cells	NULL
.	NULL

More	NULL
importantly	NULL
,	NULL
it	NULL
is	NULL
also	NULL
obvious	NULL
that	NULL
the	NULL
relative	NULL
efficiency	NULL
of	NULL
the	NULL
Spl	NULL
vs.	NULL
wild-type	NULL
kappa	NULL
promoter	NULL
is	NULL
about	NULL
the	NULL
same	NULL
for	NULL
each	NULL
of	NULL
the	NULL
four	NULL
enhancers	NULL
tested	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
there	NULL
is	NULL
neither	NULL
a	NULL
preference	NULL
of	NULL
the	NULL
immunoglobulin	NULL
enhancers	NULL
for	NULL
the	NULL
Ig	NULL
kappa	NULL
promoter	NULL
,	NULL
nor	NULL
a	NULL
preference	NULL
of	NULL
the	NULL
viral	NULL
enhancers	NULL
for	NULL
the	NULL
Spl-containing	NULL
promoter	NULL
,	NULL
as	NULL
was	NULL
already	NULL
indicated	NULL
from	NULL
the	NULL
experiments	NULL
show	NULL
in	NULL
Figure	NULL
2B	NULL
.	NULL

Transcriptional	NULL
activity	NULL
of	NULL
different	NULL
promoter	NULL
constructions	NULL
driven	NULL
by	NULL
the	NULL
SV40	NULL
enhancer	NULL
or	NULL
a	NULL
multimer	NULL
of	NULL
the	NULL
NF-xB	NULL
binding	NULL
site	NULL
In	NULL
a	NULL
final	NULL
series	NULL
of	NULL
experiments	NULL
,	NULL
we	NULL
constructed	NULL
a	NULL
series	NULL
of	NULL
promoters	NULL
where	NULL
one	NULL
or	NULL
two	NULL
binding	NULL
Na	NULL
evidence	NULL
for	NULL
enhancer/promoter	NULL
preference	NULL
sites	NULL
for	NULL
a	NULL
single	NULL
transcription	NULL
factor	NULL
were	NULL
placed	NULL
upstream	NULL
of	NULL
the	NULL
-globin	NULL
TATA	NULL
box	NULL
in	NULL
the	NULL
OVEC	NULL
reporter	NULL
plasmid	NULL
(	NULL
Westin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

These	NULL
promoters	NULL
contain	NULL
the	NULL
binding	NULL
site	NULL
for	NULL
either	NULL
the	NULL
octamer	NULL
factors	NULL
(	NULL
Wirth	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Muller	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988b	NULL
)	NULL
,	NULL
NF-xB	NULL
,	NULL
a	NULL
transcription	NULL
factor	NULL
that	NULL
is	NULL
constitutively	NULL
active	NULL
in	NULL
B	NULL
lymphocytes	NULL
,	NULL
the	NULL
so-called	NULL
Pu	NULL
box	NULL
factor	NULL
that	NULL
confers	NULL
lymphoid	NULL
:	NULL
specific	NULL
activity	NULL
(	NULL
Moreau-Gachelin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Karim	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
,	NULL
or	NULL
the	NULL
Spl	NULL
factor	NULL
(	NULL
reviewed	NULL
in	NULL
Dynan	NULL
and	NULL
Tjian	NULL
,	NULL
1985	NULL
;	NULL
Kadonaga	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

All	NULL
of	NULL
these	NULL
promoter	NULL
constructs	NULL
were	NULL
tested	NULL
with	NULL
either	NULL
the	NULL
generally	NULL
active	NULL
SV40	NULL
enhancer	NULL
or	NULL
with	NULL
eight	NULL
tandem	NULL
copies	NULL
of	NULL
the	NULL
binding	NULL
site	NULL
for	NULL
NF-xB	NULL
(	NULL
Sen	NULL
and	NULL
Baltimore	NULL
,	NULL
1986	NULL
;	NULL
Atchison	NULL
and	NULL
Perry	NULL
,	NULL
1987	NULL
;	NULL
Lenardo	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
cloning	NULL
of	NULL
NF-xB	NULL
,	NULL
see	NULL
Gosh	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Kieran	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
for	NULL
review	NULL
,	NULL
see	NULL
Lenardo	NULL
and	NULL
Baltimore	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
a	NULL
construction	NULL
containing	NULL
the	NULL
entire	NULL
B-globin	NULL
promoter	NULL
was	NULL
included	NULL
in	NULL
the	NULL
analysis	NULL
.	NULL

The	NULL
constructs	NULL
were	NULL
transfected	NULL
into	NULL
X63Ag8	NULL
myeloma	NULL
cells	NULL
together	NULL
with	NULL
the	NULL
reference	NULL
plasmid	NULL
OVEC-REFE	NULL
and	NULL
the	NULL
amount	NULL
of	NULL
specific	NULL
transcripts	NULL
was	NULL
determined	NULL
by	NULL
ribonuclease	NULL
mapping	NULL
.	NULL

When	NULL
transcription	NULL
is	NULL
driven	NULL
from	NULL
a	NULL
solitary	NULL
TATA	NULL
box	NULL
,	NULL
no	NULL
synthesis	NULL
of	NULL
reporter	NULL
gene	NULL
mRNA	NULL
is	NULL
detected	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Low	NULL
levels	NULL
of	NULL
transcription	NULL
are	NULL
observed	NULL
with	NULL
the	NULL
B-globin	NULL
promoter	NULL
,	NULL
as	NULL
well	NULL
as	NULL
with	NULL
those	NULL
constructions	NULL
containing	NULL
the	NULL
NF-xB	NULL
or	NULL
Pu	NULL
box	NULL
monomer	NULL
in	NULL
front	NULL
of	NULL
the	NULL
TATA	NULL
box	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lanes	NULL
3	NULL
,	NULL
4	NULL
,	NULL
and	NULL
6	NULL
)	NULL
.	NULL

With	NULL
the	NULL
octamer	NULL
or	NULL
the	NULL
Spl	NULL
upstream	NULL
promoter	NULL
sites	NULL
,	NULL
a	NULL
higher	NULL
level	NULL
of	NULL
specific	NULL
transcription	NULL
is	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
5	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
level	NULL
driven	NULL
by	NULL
the	NULL
two	NULL
enhancers	NULL
differs	NULL
among	NULL
the	NULL
various	NULL
promoters	NULL
.	NULL

A	NULL
very	NULL
low	NULL
level	NULL
of	NULL
expression	NULL
is	NULL
seen	NULL
from	NULL
a	NULL
crippled	NULL
promoter	NULL
consisting	NULL
of	NULL
just	NULL
a	NULL
TATA	NULL
box	NULL
,	NULL
even	NULL
if	NULL
the	NULL
SV40	NULL
enhancer	NULL
or	NULL
the	NULL
8xNF-xB	NULL
enhancer	NULL
are	NULL
present	NULL
in	NULL
a	NULL
downstream	NULL
position	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
and	NULL
C	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
insertion	NULL
of	NULL
the	NULL
various	NULL
cis-acting	NULL
motifs	NULL
in	NULL
front	NULL
of	NULL
the	NULL
TATA	NULL
box	NULL
results	NULL
in	NULL
strong	NULL
transcription	NULL
with	NULL
either	NULL
of	NULL
the	NULL
two	NULL
enhancers	NULL
linked	NULL
to	NULL
the	NULL
gene	NULL
.	NULL

The	NULL
strongest	NULL
stimulation	NULL
is	NULL
seen	NULL
with	NULL
the	NULL
octamer-	NULL
and	NULL
Spl-containing	NULL
promoters	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
and	NULL
C	NULL
,	NULL
lanes	NULL
2	NULL
and	NULL
5	NULL
)	NULL
.	NULL

These	NULL
are	NULL
also	NULL
the	NULL
promoters	NULL
which	NULL
by	NULL
themselves	NULL
give	NULL
the	NULL
highest	NULL
basal	NULL
activity	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

When	NULL
directly	NULL
compared	NULL
,	NULL
both	NULL
enhancers	NULL
analyzed	NULL
activate	NULL
a	NULL
particular	NULL
promoter	NULL
to	NULL
about	NULL
the	NULL
same	NULL
extent	NULL
(	NULL
compare	NULL
Fig	NULL
.	NULL

4B	NULL
and	NULL
C	NULL
,	NULL
lanes	NULL
2-6	NULL
)	NULL
.	NULL

Although	NULL
77	NULL
1	NULL
2	NULL
Â°3	NULL
4.5	NULL
6	NULL
7	NULL
Figure	NULL
4	NULL
.	NULL

Activity	NULL
of	NULL
B-globin	NULL
promoter	NULL
derivatives	NULL
with	NULL
either	NULL
of	NULL
two	NULL
enhancers	NULL
.	NULL

The	NULL
level	NULL
of	NULL
transcription	NULL
was	NULL
measured	NULL
from	NULL
different	NULL
promoters	NULL
without	NULL
an	NULL
enhancer	NULL
(	NULL
A	NULL
)	NULL
,	NULL
with	NULL
the	NULL
SV40	NULL
enhancer	NULL
(	NULL
B	NULL
)	NULL
,	NULL
or	NULL
with	NULL
eight	NULL
NF-xB	NULL
sites	NULL
(	NULL
C	NULL
)	NULL
.	NULL

The	NULL
constructs	NULL
used	NULL
are	NULL
schematically	NULL
drawn	NULL
in	NULL
Figure	NULL
1C	NULL
.	NULL

The	NULL
following	NULL
promoters	NULL
were	NULL
tested	NULL
:	NULL
TATA	NULL
box	NULL
alone	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
;	NULL
the	NULL
octamer	NULL
motif	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
;	NULL
the	NULL
NF-xB	NULL
binding	NULL
site	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
;	NULL
the	NULL
Pu	NULL
box	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
;	NULL
the	NULL
GC	NULL
box	NULL
,	NULL
recognized	NULL
by	NULL
the	NULL
Spl	NULL
transcription	NULL
factor	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
;	NULL
and	NULL
the	NULL
entire	NULL
-globin	NULL
promoter	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

The	NULL
constructs	NULL
were	NULL
transfected	NULL
into	NULL
X63Ag8	NULL
myeloma	NULL
cells	NULL
and	NULL
the	NULL
amount	NULL
of	NULL
B-globin	NULL
mRNA	NULL
quantitated	NULL
by	NULL
RNase	NULL
mapping	NULL
.	NULL

ct	NULL
indicates	NULL
correctly	NULL
initiated	NULL
transcripts	NULL
,	NULL
and	NULL
ref	NULL
indicates	NULL
the	NULL
transcripts	NULL
from	NULL
OVEC-REF	NULL
(	NULL
Westin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
which	NULL
was	NULL
included	NULL
as	NULL
an	NULL
internal	NULL
reference	NULL
for	NULL
transfection	NULL
efficiency	NULL
.	NULL

Hpall	NULL
digested	NULL
pBR322	NULL
DNA	NULL
was	NULL
used	NULL
as	NULL
size	NULL
marker	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

78	NULL
there	NULL
may	NULL
be	NULL
small	NULL
variations	NULL
in	NULL
this	NULL
set	NULL
of	NULL
experiments	NULL
(	NULL
for	NULL
example	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
transcription	NULL
is	NULL
some	NULL
2-3	NULL
times	NULL
more	NULL
efficient	NULL
when	NULL
the	NULL
octamer-containing	NULL
promoter	NULL
is	NULL
linked	NULL
to	NULL
the	NULL
``	NULL
NF-xB	NULL
enhancer	NULL
``	NULL
as	NULL
compared	NULL
to	NULL
the	NULL
SV40	NULL
enhancer	NULL
)	NULL
,	NULL
we	NULL
do	NULL
not	NULL
observe	NULL
a	NULL
marked	NULL
preferential	NULL
interaction	NULL
for	NULL
any	NULL
of	NULL
the	NULL
enhancer/	NULL
promoter	NULL
combinations	NULL
.	NULL

Discussion	NULL
No	NULL
general	NULL
evidence	NULL
for	NULL
enhancer/	NULL
promoter	NULL
preference	NULL
It	NULL
is	NULL
well	NULL
established	NULL
that	NULL
an	NULL
enhancer	NULL
and	NULL
a	NULL
promoter	NULL
can	NULL
act	NULL
synergistically	NULL
to	NULL
yield	NULL
a	NULL
level	NULL
of	NULL
transcription	NULL
greater	NULL
than	NULL
the	NULL
sum	NULL
of	NULL
the	NULL
levels	NULL
achieved	NULL
by	NULL
each	NULL
element	NULL
individually	NULL
.	NULL

We	NULL
have	NULL
tested	NULL
whether	NULL
there	NULL
are	NULL
specific	NULL
preferences	NULL
between	NULL
certain	NULL
enhancers	NULL
and	NULL
promoters	NULL
.	NULL

By	NULL
transfection	NULL
into	NULL
cultured	NULL
cell	NULL
lines	NULL
,	NULL
we	NULL
have	NULL
analyzed	NULL
a	NULL
total	NULL
of	NULL
27	NULL
enhancer/promoter	NULL
combinations	NULL
,	NULL
and	NULL
we	NULL
see	NULL
no	NULL
preferential	NULL
interaction	NULL
(	NULL
more	NULL
than	NULL
a	NULL
factor	NULL
of	NULL
2-3	NULL
fold	NULL
)	NULL
between	NULL
any	NULL
given	NULL
enhancer	NULL
and	NULL
promoter	NULL
.	NULL

Since	NULL
each	NULL
enhancer	NULL
activates	NULL
all	NULL
of	NULL
the	NULL
promoters	NULL
tested	NULL
,	NULL
our	NULL
results	NULL
show	NULL
that	NULL
there	NULL
is	NULL
a	NULL
great	NULL
flexibility	NULL
in	NULL
the	NULL
interaction	NULL
between	NULL
mammalian	NULL
transcriptional	NULL
control	NULL
elements	NULL
.	NULL

When	NULL
we	NULL
initiated	NULL
our	NULL
studies	NULL
,	NULL
we	NULL
expected	NULL
to	NULL
find	NULL
cases	NULL
of	NULL
exclusive	NULL
or	NULL
at	NULL
least	NULL
particularly	NULL
high-activity	NULL
with	NULL
a	NULL
naturally	NULL
occurring	NULL
enhancer/	NULL
promoter	NULL
combination	NULL
.	NULL

After	NULL
all	NULL
,	NULL
coevolution	NULL
of	NULL
components	NULL
involved	NULL
in	NULL
the	NULL
same	NULL
regulatory	NULL
pathway	NULL
is	NULL
a	NULL
common	NULL
biological	NULL
phenomenon	NULL
.	NULL

Not	NULL
unexpectedly	NULL
,	NULL
regulatory	NULL
sequences	NULL
of	NULL
genes	NULL
transcribed	NULL
by	NULL
different	NULL
RNA	NULL
polymerases	NULL
can	NULL
have	NULL
diverged	NULL
such	NULL
that	NULL
they	NULL
are	NULL
not	NULL
compatible	NULL
,	NULL
such	NULL
as	NULL
a	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
(	NULL
RNA	NULL
polymerase	NULL
II	NULL
)	NULL
and	NULL
an	NULL
rDNA	NULL
enhancer	NULL
(	NULL
RNA	NULL
polymerase	NULL
I	NULL
)	NULL
(	NULL
Pape	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

Also	NULL
,	NULL
the	NULL
highly	NULL
specialized	NULL
U2	NULL
snRNA	NULL
genes	NULL
,	NULL
even	NULL
though	NULL
transcribed	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
,	NULL
can	NULL
not	NULL
be	NULL
activated	NULL
by	NULL
an	NULL
SV40	NULL
enhancer	NULL
(	NULL
Tanaka	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
some	NULL
reports	NULL
on	NULL
preferential	NULL
activity	NULL
of	NULL
certain	NULL
enhancer/promoter	NULL
combinations	NULL
(	NULL
see	NULL
below	NULL
)	NULL
,	NULL
one	NULL
set	NULL
of	NULL
observations	NULL
seems	NULL
to	NULL
strengthen	NULL
the	NULL
argument	NULL
for	NULL
coevolution	NULL
resulting	NULL
in	NULL
made-to-	NULL
measure	NULL
enhancer/	NULL
promoter	NULL
combinations	NULL
.	NULL

In	NULL
several	NULL
of	NULL
the	NULL
cases	NULL
analyzed	NULL
so	NULL
far	NULL
,	NULL
including	NULL
the	NULL
Ig	NULL
heavy	NULL
chain	NULL
locus	NULL
,	NULL
binding	NULL
sites	NULL
for	NULL
a	NULL
given	NULL
transcription	NULL
factor	NULL
are	NULL
present	NULL
both	NULL
in	NULL
a	NULL
enhancer	NULL
and	NULL
in	NULL
a	NULL
proxi-	NULL
Kermekchiev	NULL
et	NULL
al	NULL
.	NULL

mal	NULL
promoter	NULL
region	NULL
(	NULL
see	NULL
,	NULL
for	NULL
example	NULL
,	NULL
Gerster	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Landschulz	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Wall	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

In	NULL
the	NULL
Ig	NULL
heavy	NULL
chain	NULL
genes	NULL
,	NULL
the	NULL
octamer	NULL
motif	NULL
ATGCAAAT	NULL
is	NULL
present	NULL
both	NULL
in	NULL
the	NULL
promoter	NULL
and	NULL
,	NULL
in	NULL
inverse	NULL
orientation	NULL
,	NULL
the	NULL
enhancer	NULL
.	NULL

Thus	NULL
it	NULL
was	NULL
tempting	NULL
to	NULL
speculate	NULL
that	NULL
,	NULL
for	NULL
example	NULL
,	NULL
dimerization	NULL
of	NULL
octamer	NULL
factors	NULL
would	NULL
link	NULL
up	NULL
the	NULL
enhancer	NULL
and	NULL
promoter	NULL
.	NULL

A	NULL
precedent	NULL
for	NULL
such	NULL
an	NULL
interaction	NULL
is	NULL
found	NULL
in	NULL
pro-karyotes	NULL
:	NULL
cooperative	NULL
repressor	NULL
binding	NULL
can	NULL
bring	NULL
together	NULL
operator	NULL
sites	NULL
over	NULL
distances	NULL
of	NULL
more	NULL
than	NULL
one	NULL
hundred	NULL
bp	NULL
,	NULL
with	NULL
concomitant	NULL
looping	NULL
out	NULL
of	NULL
the	NULL
intervening	NULL
DNA	NULL
(	NULL
for	NULL
reviews	NULL
see	NULL
Ptashne	NULL
,	NULL
1986	NULL
;	NULL
Lobell	NULL
and	NULL
Schleif	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

However	NULL
,	NULL
so	NULL
far	NULL
no	NULL
evidence	NULL
has	NULL
been	NULL
obtained	NULL
for	NULL
cooperative	NULL
binding	NULL
of	NULL
a	NULL
factor	NULL
over	NULL
the	NULL
long	NULL
distances	NULL
that	NULL
can	NULL
separate	NULL
enhancers	NULL
and	NULL
promoters	NULL
,	NULL
even	NULL
though	NULL
enhancer	NULL
and	NULL
promoter	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
functionally	NULL
interact	NULL
when	NULL
brought	NULL
in	NULL
close	NULL
proximity	NULL
via	NULL
a	NULL
protein	NULL
bridge	NULL
(	NULL
Muller	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
for	NULL
review	NULL
see	NULL
Muller	NULL
and	NULL
Schaffner	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
our	NULL
present	NULL
experiments	NULL
fail	NULL
to	NULL
show	NULL
a	NULL
significant	NULL
improvement	NULL
in	NULL
activity	NULL
when	NULL
the	NULL
enhancer	NULL
and	NULL
promoter	NULL
contain	NULL
the	NULL
same	NULL
factor	NULL
binding	NULL
site	NULL
.	NULL

A	NULL
similar	NULL
lack	NULL
of	NULL
preference	NULL
is	NULL
also	NULL
found	NULL
in	NULL
HeLa	NULL
cells	NULL
when	NULL
an	NULL
enhancer	NULL
with	NULL
multiple	NULL
glucocorti-coid-responsive	NULL
elements	NULL
(	NULL
GREs	NULL
)	NULL
is	NULL
tested	NULL
with	NULL
GRE	NULL
promoters	NULL
versus	NULL
an	NULL
Spl	NULL
promoter	NULL
(	NULL
Schatt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
may	NULL
be	NULL
that	NULL
the	NULL
interaction	NULL
between	NULL
factors	NULL
bound	NULL
to	NULL
enhancers	NULL
and	NULL
promoters	NULL
is	NULL
not	NULL
direct	NULL
,	NULL
as	NULL
in	NULL
prokaryotic	NULL
repressor	NULL
binding	NULL
,	NULL
but	NULL
rather	NULL
mediated	NULL
by	NULL
protein/	NULL
protein	NULL
interaction	NULL
with	NULL
additional	NULL
factors	NULL
and/or	NULL
RNA	NULL
polymerase	NULL
itself	NULL
(	NULL
reviewed	NULL
in	NULL
Lewin	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

The	NULL
DNA	NULL
constructions	NULL
tested	NULL
by	NULL
us	NULL
include	NULL
combinations	NULL
of	NULL
the	NULL
Ig	NULL
kappa	NULL
promoter	NULL
with	NULL
Ig	NULL
kappa	NULL
and	NULL
Ig	NULL
heavy	NULL
chain	NULL
enhancers	NULL
,	NULL
and	NULL
of	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
with	NULL
its	NULL
enhancer	NULL
.	NULL

None	NULL
of	NULL
them	NULL
shows	NULL
preferential	NULL
activity	NULL
.	NULL

Not	NULL
:	NULL
ably	NULL
,	NULL
we	NULL
do	NULL
not	NULL
see	NULL
particularly	NULL
high	NULL
gene	NULL
expression	NULL
when	NULL
the	NULL
immunoglobulin	NULL
kappa	NULL
enhancer	NULL
(	NULL
or	NULL
the	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
enhancer	NULL
)	NULL
is	NULL
used	NULL
to	NULL
activate	NULL
a	NULL
kappa	NULL
gene	NULL
promoter	NULL
.	NULL

Meyer	NULL
and	NULL
Neuberger	NULL
(	NULL
1989	NULL
)	NULL
have	NULL
also	NULL
found	NULL
weak	NULL
activity	NULL
of	NULL
the	NULL
kappa	NULL
intron	NULL
enhancer	NULL
with	NULL
a	NULL
B-globin	NULL
promoter	NULL
,	NULL
and	NULL
they	NULL
pointed	NULL
out	NULL
the	NULL
existence	NULL
of	NULL
a	NULL
second	NULL
,	NULL
stronger	NULL
kappa	NULL
gene	NULL
enhancer	NULL
far	NULL
downstream	NULL
of	NULL
the	NULL
constant	NULL
region	NULL
which	NULL
was	NULL
required	NULL
for	NULL
strong	NULL
ac-tivation	NULL
.	NULL

However	NULL
,	NULL
the	NULL
Ig	NULL
kappa	NULL
promoter/intron	NULL
enhancer	NULL
combination	NULL
was	NULL
previously	NULL
reported	NULL
No	NULL
evidence	NULL
for	NULL
enhancer/promoter	NULL
preference	NULL
to	NULL
be	NULL
preferentially	NULL
active	NULL
(	NULL
Garcia	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

The	NULL
difference	NULL
between	NULL
our	NULL
results	NULL
and	NULL
those	NULL
of	NULL
Garcia	NULL
et	NULL
al	NULL
.	NULL

could	NULL
be	NULL
due	NULL
to	NULL
differences	NULL
in	NULL
the	NULL
particular	NULL
DNA	NULL
constructs	NULL
or	NULL
B	NULL
cell	NULL
lines	NULL
used	NULL
.	NULL

Some	NULL
data	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
herpes	NULL
virus	NULL
thymidine	NULL
kinase	NULL
gene	NULL
(	NULL
Parslow	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
and	NULL
the	NULL
alcohol	NULL
dehydrogenase	NULL
gene	NULL
in	NULL
Drosophila	NULL
(	NULL
Fischer	NULL
and	NULL
Maniatis	NULL
,	NULL
1988	NULL
)	NULL
can	NULL
be	NULL
explained	NULL
by	NULL
selective	NULL
enhancer/promoter	NULL
interaction	NULL
.	NULL

Re-cently	NULL
,	NULL
Vincent	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
have	NULL
inserted	NULL
multiple	NULL
copies	NULL
of	NULL
a	NULL
synthetic	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
``	NULL
engrailed	NULL
``	NULL
protein	NULL
upstream	NULL
of	NULL
different	NULL
promoters	NULL
.	NULL

These	NULL
combinations	NULL
have	NULL
a	NULL
more	NULL
restricted	NULL
and	NULL
specific	NULL
ability	NULL
to	NULL
enhance	NULL
transcription	NULL
when	NULL
assayed	NULL
in	NULL
transgenic	NULL
fly	NULL
embryos	NULL
as	NULL
compared	NULL
to	NULL
a	NULL
more	NULL
permissive	NULL
enhancer/promoter	NULL
interaction	NULL
in	NULL
transiently	NULL
transfected	NULL
tissue	NULL
culture	NULL
cells	NULL
.	NULL

Nevertheless	NULL
,	NULL
others	NULL
have	NULL
selected	NULL
for	NULL
a	NULL
great	NULL
variety	NULL
of	NULL
stage-and	NULL
cell	NULL
type-specific	NULL
enhancers	NULL
in	NULL
Drosophila	NULL
by	NULL
using	NULL
one	NULL
common	NULL
promoter	NULL
(	NULL
Bellen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Wilson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

Even	NULL
though	NULL
only	NULL
one	NULL
promoter	NULL
was	NULL
tested	NULL
,	NULL
these	NULL
data	NULL
are	NULL
also	NULL
compatible	NULL
with	NULL
a	NULL
permissive	NULL
enhancer/promoter	NULL
interaction	NULL
.	NULL

Evolution	NULL
by	NULL
enhancer	NULL
shuffling	NULL
?	NULL

There	NULL
could	NULL
well	NULL
be	NULL
cases	NULL
of	NULL
preferential	NULL
enhancer/promoter	NULL
interaction	NULL
.	NULL

Even	NULL
subtle	NULL
differences	NULL
in	NULL
responsiveness	NULL
could	NULL
be	NULL
important	NULL
during	NULL
embryogenesis	NULL
,	NULL
when	NULL
gene	NULL
dosage	NULL
appears	NULL
to	NULL
be	NULL
most	NULL
critical	NULL
.	NULL

Nevertheless	NULL
,	NULL
our	NULL
data	NULL
with	NULL
quantitative	NULL
transcription	NULL
mapping	NULL
in	NULL
transfected	NULL
B	NULL
cell	NULL
lines	NULL
imply	NULL
that	NULL
generally	NULL
a	NULL
given	NULL
promoter	NULL
can	NULL
respond	NULL
to	NULL
any	NULL
enhancer	NULL
(	NULL
assuming	NULL
,	NULL
of	NULL
course	NULL
,	NULL
that	NULL
they	NULL
are	NULL
active	NULL
at	NULL
all	NULL
in	NULL
the	NULL
particular	NULL
cell	NULL
type	NULL
)	NULL
.	NULL

This	NULL
raises	NULL
the	NULL
question	NULL
of	NULL
the	NULL
possible	NULL
biological	NULL
consequence	NULL
(	NULL
s	NULL
)	NULL
of	NULL
this	NULL
phenomenon	NULL
.	NULL

One	NULL
might	NULL
argue	NULL
that	NULL
all	NULL
enhancers	NULL
and	NULL
promoters	NULL
are	NULL
channeling	NULL
their	NULL
actions	NULL
through	NULL
some	NULL
common	NULL
element	NULL
,	NULL
eg	NULL
.	NULL

,	NULL
RNA	NULL
polymerase	NULL
II	NULL
,	NULL
and	NULL
therefore	NULL
can	NULL
not	NULL
diverge	NULL
from	NULL
a	NULL
ubiquitous	NULL
function	NULL
.	NULL

However	NULL
,	NULL
in	NULL
procaryotes	NULL
there	NULL
is	NULL
strong	NULL
selectivity	NULL
:	NULL
operators	NULL
in	NULL
upstream	NULL
and	NULL
promoter-proximal	NULL
positions	NULL
must	NULL
bind	NULL
the	NULL
same	NULL
factor	NULL
to	NULL
interact	NULL
via	NULL
DNA	NULL
looping	NULL
(	NULL
for	NULL
the	NULL
ara	NULL
operon	NULL
,	NULL
see	NULL
Lobell	NULL
and	NULL
Schleif	NULL
,	NULL
1990	NULL
;	NULL
for	NULL
the	NULL
lac	NULL
operon	NULL
,	NULL
see	NULL
Kramer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

If	NULL
in	NULL
eukaryotes	NULL
a	NULL
particular	NULL
enhancer	NULL
is	NULL
able	NULL
to	NULL
activate	NULL
almost	NULL
any	NULL
promoter	NULL
brought	NULL
under	NULL
its	NULL
domain	NULL
of	NULL
influence	NULL
,	NULL
we	NULL
speculate	NULL
that	NULL
this	NULL
may	NULL
facilitate	NULL
the	NULL
generation	NULL
of	NULL
new	NULL
regulatory	NULL
pathways	NULL
,	NULL
thus	NULL
accelerating	NULL
ev-olution	NULL
.	NULL

We	NULL
also	NULL
note	NULL
a	NULL
possible	NULL
similarity	NULL
of	NULL
79	NULL
this	NULL
phenomenon	NULL
to	NULL
the	NULL
so-called	NULL
exon	NULL
shuffling	NULL
(	NULL
Gilbert	NULL
,	NULL
1978	NULL
)	NULL
,	NULL
in	NULL
which	NULL
a	NULL
compatibility	NULL
of	NULL
heterologous	NULL
5	NULL
and	NULL
3	NULL
'	NULL
splice	NULL
sites	NULL
makes	NULL
possible	NULL
the	NULL
production	NULL
of	NULL
new	NULL
combinations	NULL
of	NULL
protein	NULL
domains	NULL
,	NULL
as	NULL
a	NULL
result	NULL
of	NULL
translocation	NULL
events	NULL
.	NULL

In	NULL
the	NULL
realm	NULL
of	NULL
transcription	NULL
,	NULL
multiple	NULL
enhancers	NULL
controlling	NULL
the	NULL
same	NULL
gene	NULL
may	NULL
have	NULL
been	NULL
acquired	NULL
by	NULL
enhancer	NULL
shuffling	NULL
.	NULL

For	NULL
example	NULL
,	NULL
expression	NULL
of	NULL
the	NULL
alpha	NULL
fetoprotein	NULL
gene	NULL
in	NULL
multiple	NULL
cell	NULL
types	NULL
is	NULL
governed	NULL
by	NULL
three	NULL
separate	NULL
enhancers	NULL
spread	NULL
over	NULL
a	NULL
sequence	NULL
of	NULL
4	NULL
kb	NULL
(	NULL
Camper	NULL
and	NULL
Tilghman	NULL
,	NULL
1989	NULL
)	NULL
.	NULL

In	NULL
Drosophila	NULL
embryos	NULL
,	NULL
separate	NULL
DNA	NULL
regions	NULL
control	NULL
expression	NULL
in	NULL
ecto/mesoderm	NULL
and	NULL
neural	NULL
precursors	NULL
cells	NULL
(	NULL
Hiromi	NULL
and	NULL
Gehring	NULL
,	NULL
1987	NULL
;	NULL
Pick	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

Another	NULL
possible	NULL
example	NULL
is	NULL
lysozyme	NULL
,	NULL
an	NULL
antibacterial	NULL
enzyme	NULL
,	NULL
produced	NULL
in	NULL
chicken	NULL
macrophages	NULL
and	NULL
also	NULL
deposited	NULL
in	NULL
enormous	NULL
quantities	NULL
in	NULL
egg	NULL
white	NULL
.	NULL

Expression	NULL
in	NULL
macrophages	NULL
and	NULL
in	NULL
oviduct	NULL
cells	NULL
is	NULL
controlled	NULL
by	NULL
separate	NULL
enhancers	NULL
with	NULL
a	NULL
common	NULL
promoter	NULL
(	NULL
Thei-sen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Steiner	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

It	NULL
is	NULL
also	NULL
interesting	NULL
to	NULL
note	NULL
that	NULL
in	NULL
different	NULL
animal	NULL
classes	NULL
,	NULL
various	NULL
proteins	NULL
such	NULL
as	NULL
lactate	NULL
dehydro-genase	NULL
,	NULL
enolase	NULL
,	NULL
and	NULL
a	NULL
small	NULL
heat	NULL
shock	NULL
protein	NULL
have	NULL
been	NULL
recruited	NULL
to	NULL
become	NULL
the	NULL
major	NULL
lens	NULL
crystallin	NULL
proteins	NULL
(	NULL
De	NULL
Jong	NULL
et	NULL
al	NULL
.	NULL

1989	NULL
)	NULL
.	NULL

One	NULL
explanation	NULL
for	NULL
this	NULL
new	NULL
function	NULL
could	NULL
be	NULL
a	NULL
translocation	NULL
event	NULL
involving	NULL
the	NULL
particular	NULL
gene	NULL
and	NULL
a	NULL
lens	NULL
cell-specific	NULL
enhancer	NULL
.	NULL

In	NULL
special	NULL
cases	NULL
,	NULL
however	NULL
,	NULL
such	NULL
mixing	NULL
and	NULL
matching	NULL
phenomena	NULL
may	NULL
have	NULL
adverse	NULL
effects	NULL
,	NULL
resulting	NULL
in	NULL
ectopic	NULL
expression	NULL
of	NULL
a	NULL
proto-oncogene	NULL
and	NULL
thus	NULL
contributing	NULL
to	NULL
malignant	NULL
transformation	NULL
(	NULL
reviewed	NULL
in	NULL
Lang	NULL
and	NULL
Spandidos	NULL
,	NULL
1988	NULL
)	NULL
.	NULL

Reprogramming	NULL
of	NULL
genes	NULL
during	NULL
evolution	NULL
may	NULL
happen	NULL
frequently	NULL
in	NULL
many	NULL
organisms	NULL
,	NULL
including	NULL
Drosophila	NULL
,	NULL
where	NULL
the	NULL
spacer	NULL
DNA	NULL
between	NULL
genes	NULL
contains	NULL
a	NULL
great	NULL
variety	NULL
of	NULL
enhancers	NULL
with	NULL
particular	NULL
temporal	NULL
and	NULL
cell	NULL
type	NULL
specificities	NULL
(	NULL
Wilson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Bellen	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
higher	NULL
eukaryotes	NULL
the	NULL
most	NULL
convenient	NULL
way	NULL
to	NULL
extend	NULL
or	NULL
restrict	NULL
the	NULL
specificity	NULL
of	NULL
a	NULL
given	NULL
gene	NULL
may	NULL
be	NULL
by	NULL
adding	NULL
or	NULL
deleting	NULL
remote	NULL
enhancer	NULL
sequences	NULL
.	NULL

Acknowledgments	NULL
We	NULL
are	NULL
grateful	NULL
to	NULL
Michael	NULL
Schatt	NULL
,	NULL
Dr.	NULL
David	NULL
Arnosti	NULL
,	NULL
and	NULL
Dr.	NULL
Keith	NULL
Harshman	NULL
for	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
and	NULL
for	NULL
valuable	NULL
discussions	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Silvia	NULL
Oberholzer	NULL
for	NULL
help	NULL
in	NULL
the	NULL
preparation	NULL
of	NULL
the	NULL
manuscript	NULL
,	NULL
Rudolph	NULL
Meszlenyi	NULL
for	NULL
synthesiz-	NULL
80	NULL
ing	NULL
the	NULL
oligonucleotides	NULL
,	NULL
and	NULL
Fritz	NULL
Ochsenbein	NULL
for	NULL
graphic	NULL
artwork	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
Canton	NULL
of	NULL
Zurich	NULL
and	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Swiss	NULL
National	NULL
Science	NULL
Foundation	NULL
,	NULL
No	NULL
.	NULL

31-25650.88	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publishing	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
USC	NULL
Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

References	NULL
T.	NULL
Abel	NULL
and	NULL
T.	NULL
Maniatis	NULL
(	NULL
1990	NULL
)	NULL
,	NULL
Nature	NULL
341	NULL
,	NULL
24-25	NULL
.	NULL

M.	NULL
L.	NULL
Atchison	NULL
and	NULL
R.	NULL
P.	NULL
Perry	NULL
(	NULL
1987	NULL
)	NULL
,	NULL
Cell	NULL
48	NULL
,	NULL
121-128	NULL
.	NULL

[	NULL
J.	NULL
Banerji	NULL
,	NULL
S.	NULL
Rusconi	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
(	NULL
1981	NULL
)	NULL
,	NULL
Cell	NULL
27	NULL
,	NULL
299-308	NULL
.	NULL

[	NULL
J.	NULL
Banerji	NULL
,	NULL
L.	NULL
Olson	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
(	NULL
1983	NULL
)	NULL
,	NULL
Cell	NULL
33	NULL
,	NULL
729-740	NULL
.	NULL

C.	NULL
Benoist	NULL
and	NULL
P.	NULL
Chambon	NULL
(	NULL
1981	NULL
)	NULL
,	NULL
Nature	NULL
290	NULL
,	NULL
310-315	NULL
.	NULL

H.	NULL
J.	NULL
Bellen	NULL
,	NULL
C.	NULL
J.	NULL
O'Kane	NULL
,	NULL
C.	NULL
Wilson	NULL
,	NULL
U.	NULL
Grossniklaus	NULL
,	NULL
R.	NULL
K.	NULL
Pearson	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Gehring	NULL
(	NULL
1989	NULL
)	NULL
,	NULL
Genes	NULL
Dev	NULL
3	NULL
,	NULL
1288-1300	NULL
.	NULL

S.	NULL
Camper	NULL
and	NULL
S.	NULL
Tilghman	NULL
(	NULL
1989	NULL
)	NULL
,	NULL
Genes	NULL
Dev	NULL
3	NULL
,	NULL
537-546	NULL
.	NULL

A.	NULL
D.	NULL
Carter	NULL
,	NULL
B.	NULL
K.	NULL
Felber	NULL
,	NULL
M.	NULL
Walling	NULL
,	NULL
MFE	NULL
.	NULL

Jubier	NULL
,	NULL
C.	NULL
J.	NULL
Schmidt	NULL
,	NULL
and	NULL
D.	NULL
H.	NULL
Hamer	NULL
(	NULL
1984	NULL
)	NULL
,	NULL
Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
81	NULL
,	NULL
7392-7396	NULL
.	NULL

T.	NULL
Curran	NULL
and	NULL
R.	NULL
B.	NULL
Franza	NULL
(	NULL
1988	NULL
)	NULL
,	NULL
Cell	NULL
55	NULL
,	NULL
395-397	NULL
.	NULL

W.	NULL
W.	NULL
DeJong	NULL
,	NULL
W.	NULL
Hendriks	NULL
,	NULL
J.	NULL
W.	NULL
M.	NULL
Mulders	NULL
,	NULL
and	NULL
H.	NULL
Bloemendal	NULL
(	NULL
1989	NULL
)	NULL
,	NULL
Trends	NULL
Biol	NULL
Sci	NULL
14	NULL
,	NULL
365-368	NULL
.	NULL

J	NULL
.	NULL

De	NULL
Villiers	NULL
and	NULL
W.	NULL
Schaffner	NULL
(	NULL
1983	NULL
)	NULL
,	NULL
in	NULL
Techniques	NULL
in	NULL
the	NULL
Life	NULL
Sciences	NULL
,	NULL
B5	NULL
,	NULL
Techniques	NULL
in	NULL
Nucleic	NULL
Acid	NULL
Biochemistry	NULL
B507	NULL
(	NULL
R.	NULL
A.	NULL
Flavell	NULL
,	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Else-vier	NULL
Scientific	NULL
Publishers	NULL
Ireland	NULL
Ltd.	NULL
,	NULL
pp	NULL
.	NULL

1-20	NULL
.	NULL

M.	NULL
Dreyfus	NULL
,	NULL
N.	NULL
Doyen	NULL
,	NULL
and	NULL
F.	NULL
Rougeon	NULL
(	NULL
1987	NULL
)	NULL
,	NULL
EMBO	NULL
J	NULL
6	NULL
,	NULL
1685-1690	NULL
.	NULL

D.	NULL
M.	NULL
Durnam	NULL
,	NULL
J.	NULL
S.	NULL
Hoffman	NULL
,	NULL
C.	NULL
J.	NULL
Quaife	NULL
,	NULL
E.	NULL
P.	NULL
Ben-ditt	NULL
,	NULL
H.	NULL
Y.	NULL
Chen	NULL
,	NULL
R.	NULL
L.	NULL
Brinster	NULL
,	NULL
and	NULL
R.	NULL
D.	NULL
Pal-miter	NULL
(	NULL
1984	NULL
)	NULL
,	NULL
Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
81	NULL
,	NULL
1053-1056	NULL
.	NULL

W.	NULL
S.	NULL
Dynan	NULL
and	NULL
R.	NULL
Tjian	NULL
(	NULL
1983	NULL
)	NULL
,	NULL
Cell	NULL
35	NULL
,	NULL
79-87	NULL
.	NULL

W.	NULL
S.	NULL
Dynan	NULL
and	NULL
R.	NULL
Tjian	NULL
(	NULL
1985	NULL
)	NULL
,	NULL
Nature	NULL
316	NULL
,	NULL
774-778	NULL
.	NULL

F.	NULL
G.	NULL
Falkner	NULL
,	NULL
E.	NULL
Neumann	NULL
,	NULL
and	NULL
H.	NULL
G.	NULL
Zachau	NULL
(	NULL
1984	NULL
)	NULL
,	NULL
Hoppe	NULL
Seyler	NULL
's	NULL
Z	NULL
Physiol	NULL
Chem	NULL
365	NULL
,	NULL
1331-1343	NULL
.	NULL

J.	NULL
Fischer	NULL
and	NULL
T.	NULL
Maniatis	NULL
(	NULL
1988	NULL
)	NULL
,	NULL
Cell	NULL
53	NULL
,	NULL
451-461	NULL
.	NULL

J	NULL
.	NULL

Foster	NULL
,	NULL
J.	NULL
Stafford	NULL
and	NULL
C.	NULL
Queen	NULL
(	NULL
1985	NULL
)	NULL
,	NULL
Nature	NULL
315	NULL
,	NULL
423-425	NULL
.	NULL

J.	NULL
V.	NULL
Garcia	NULL
,	NULL
L.	NULL
T.	NULL
Bich	NULL
Thuy	NULL
,	NULL
J.	NULL
Stafford	NULL
,	NULL
and	NULL
C.	NULL
Queen	NULL
(	NULL
1986	NULL
)	NULL
,	NULL
Nature	NULL
322	NULL
,	NULL
383-385	NULL
.	NULL

T.	NULL
Gerster	NULL
,	NULL
P.	NULL
Matthias	NULL
,	NULL
M.	NULL
Thali	NULL
,	NULL
J.	NULL
Jiricny	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
(	NULL
1987	NULL
)	NULL
,	NULL
EMBO	NULL
J	NULL
6	NULL
,	NULL
1323-1330	NULL
.	NULL

W.	NULL
Gilbert	NULL
(	NULL
1978	NULL
)	NULL
,	NULL
Nature	NULL
271	NULL
,	NULL
501	NULL
.	NULL

S.	NULL
D.	NULL
Gillies	NULL
,	NULL
S.	NULL
L.	NULL
Morrison	NULL
,	NULL
V.	NULL
T.	NULL
Oi	NULL
,	NULL
and	NULL
S.	NULL
Tonegawa	NULL
(	NULL
1983	NULL
)	NULL
,	NULL
Cell	NULL
33	NULL
,	NULL
717-728	NULL
.	NULL

S.	NULL
Gosh	NULL
,	NULL
A.	NULL
M.	NULL
Gifford	NULL
,	NULL
L.	NULL
R.	NULL
Riviere	NULL
,	NULL
P.	NULL
Tempst	NULL
,	NULL
G.	NULL
P.	NULL
Nolan	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
(	NULL
1990	NULL
)	NULL
,	NULL
Cell	NULL
62	NULL
,	NULL
1019-1029	NULL
.	NULL

Kermekchiev	NULL
et	NULL
al	NULL
.	NULL

R.	NULL
Grosschedl	NULL
and	NULL
D.	NULL
Baltimore	NULL
(	NULL
1985	NULL
)	NULL
,	NULL
Cell	NULL
41	NULL
,	NULL
885-897	NULL
.	NULL

Y.	NULL
Hiromi	NULL
and	NULL
W.	NULL
J.	NULL
Gehring	NULL
(	NULL
1987	NULL
)	NULL
,	NULL
Cell	NULL
50	NULL
,	NULL
963-974	NULL
.	NULL

Y-E.	NULL
Hu	NULL
,	NULL
B.	NULL
Luscher	NULL
,	NULL
A.	NULL
Admon	NULL
,	NULL
N.	NULL
Mermod	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
(	NULL
1990	NULL
)	NULL
,	NULL
Genes	NULL
Dev	NULL
4	NULL
,	NULL
1741-1752	NULL
.	NULL

P.	NULL
F.	NULL
Johnson	NULL
and	NULL
S.	NULL
L.	NULL
McKnight	NULL
(	NULL
1989	NULL
)	NULL
,	NULL
Ann	NULL
Rev	NULL
Biochem	NULL
58	NULL
,	NULL
799-839	NULL
.	NULL

N.	NULL
Jones	NULL
(	NULL
1990	NULL
)	NULL
,	NULL
Cell	NULL
61	NULL
,	NULL
9-11	NULL
.	NULL

J.	NULL
T.	NULL
Kadonaga	NULL
,	NULL
K.	NULL
A.	NULL
Jones	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
(	NULL
1986	NULL
)	NULL
,	NULL
Trends	NULL
Biochem	NULL
Sci	NULL
11	NULL
,	NULL
20-23	NULL
.	NULL

M.	NULL
Karin	NULL
,	NULL
A.	NULL
Haslinger	NULL
,	NULL
H.	NULL
Holtgreve	NULL
,	NULL
R.	NULL
I.	NULL
Richards	NULL
,	NULL
P.	NULL
Krauter	NULL
,	NULL
H.	NULL
M.	NULL
Westphal	NULL
,	NULL
and	NULL
M.	NULL
Beato	NULL
(	NULL
1984	NULL
)	NULL
,	NULL
Nature	NULL
308	NULL
,	NULL
513-519	NULL
.	NULL

E.	NULL
D.	NULL
Karim	NULL
,	NULL
L.	NULL
D.	NULL
Urness	NULL
,	NULL
C.	NULL
S.	NULL
Thummel	NULL
,	NULL
M.	NULL
J.	NULL
Klemsz	NULL
,	NULL
S.	NULL
R.	NULL
McKercher	NULL
,	NULL
A.	NULL
Celada	NULL
,	NULL
C.	NULL
Van	NULL
Beveren	NULL
,	NULL
R.	NULL
A.	NULL
Maki	NULL
,	NULL
C.	NULL
V.	NULL
Gunther	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Nye	NULL
,	NULL
and	NULL
B.	NULL
J.	NULL
Graves	NULL
(	NULL
1990	NULL
)	NULL
,	NULL
Genes	NULL
Dev	NULL
4	NULL
,	NULL
1451-1453	NULL
.	NULL

M.	NULL
Kieran	NULL
,	NULL
V.	NULL
Blank	NULL
,	NULL
F.	NULL
Logeat	NULL
,	NULL
J.	NULL
Vandekerckhove	NULL
,	NULL
F.	NULL
Lottspeich	NULL
,	NULL
O	NULL
.	NULL

Le	NULL
Bail	NULL
,	NULL
M.	NULL
B	NULL
.	NULL

Urban	NULL
,	NULL
P.	NULL
Kou-rilsky	NULL
,	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
,	NULL
and	NULL
A.	NULL
Israel	NULL
(	NULL
1990	NULL
)	NULL
,	NULL
Cell	NULL
62	NULL
,	NULL
1007-1018	NULL
.	NULL

H.	NULL
Kramer	NULL
,	NULL
M.	NULL
Niemoller	NULL
,	NULL
M.	NULL
Amouyal	NULL
,	NULL
B.	NULL
Revet	NULL
,	NULL
B.	NULL
Wilcken-Bergmann	NULL
,	NULL
and	NULL
B.	NULL
Miiller-Hill	NULL
(	NULL
1987	NULL
)	NULL
,	NULL
EMBO	NULL
J	NULL
6	NULL
,	NULL
1481-1491	NULL
.	NULL

W.	NULL
H.	NULL
Landschulz	NULL
,	NULL
P.	NULL
F.	NULL
Johnson	NULL
,	NULL
E.	NULL
Y.	NULL
Adashi	NULL
,	NULL
B.	NULL
J.	NULL
Graves	NULL
,	NULL
and	NULL
S.	NULL
L.	NULL
McKnight	NULL
(	NULL
1988	NULL
)	NULL
,	NULL
Genes	NULL
Dev	NULL
2	NULL
,	NULL
786-800	NULL
.	NULL

J.	NULL
C.	NULL
Lang	NULL
and	NULL
D.	NULL
A.	NULL
Spandidos	NULL
(	NULL
1986	NULL
)	NULL
,	NULL
Anticancer	NULL
Res	NULL
6	NULL
,	NULL
437-450	NULL
.	NULL

M.	NULL
Lenardo	NULL
,	NULL
J.	NULL
W.	NULL
Pierce	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
(	NULL
1987	NULL
)	NULL
,	NULL
Science	NULL
236	NULL
,	NULL
1573-1577	NULL
.	NULL

M.	NULL
Lenardo	NULL
and	NULL
D.	NULL
Baltimore	NULL
(	NULL
1989	NULL
)	NULL
,	NULL
Cell	NULL
58	NULL
,	NULL
227-229	NULL
.	NULL

B.	NULL
Levinson	NULL
,	NULL
G.	NULL
Khoury	NULL
,	NULL
G.	NULL
Van	NULL
de	NULL
Woude	NULL
,	NULL
and	NULL
P.	NULL
Gruss	NULL
(	NULL
1982	NULL
)	NULL
,	NULL
Nature	NULL
295	NULL
,	NULL
568-572	NULL
.	NULL

B.	NULL
Lewin	NULL
(	NULL
1990	NULL
)	NULL
,	NULL
Cell	NULL
61	NULL
,	NULL
1161-1164	NULL
.	NULL

R.	NULL
B.	NULL
Lobell	NULL
and	NULL
R.	NULL
Schleif	NULL
(	NULL
1990	NULL
)	NULL
,	NULL
Science	NULL
250	NULL
,	NULL
528-532	NULL
.	NULL

T.	NULL
Maniatis	NULL
,	NULL
E.	NULL
Fritsch	NULL
,	NULL
and	NULL
J.	NULL
Sambrook	NULL
(	NULL
1982	NULL
)	NULL
,	NULL
Molecular	NULL
Cloning	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
Press	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
.	NULL

T.	NULL
Maniatis	NULL
,	NULL
S.	NULL
Goodbourn	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Fischer	NULL
(	NULL
1987	NULL
)	NULL
,	NULL
Science	NULL
236	NULL
,	NULL
1237-1245	NULL
.	NULL

J.	NULL
Mason	NULL
,	NULL
G.	NULL
Williams	NULL
,	NULL
and	NULL
M.	NULL
Neuberger	NULL
(	NULL
1985	NULL
)	NULL
,	NULL
Cell	NULL
41	NULL
,	NULL
479-487	NULL
.	NULL

D.	NULL
J.	NULL
Mathis	NULL
and	NULL
P.	NULL
Chambon	NULL
(	NULL
1981	NULL
)	NULL
,	NULL
Nature	NULL
290	NULL
,	NULL
310-315	NULL
.	NULL

D.	NULL
A.	NULL
Melton	NULL
,	NULL
P.	NULL
A.	NULL
Krieg	NULL
,	NULL
M.	NULL
R.	NULL
Rebagliati	NULL
,	NULL
T.	NULL
Maniatis	NULL
,	NULL
K.	NULL
Zinn	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Green	NULL
(	NULL
1984	NULL
)	NULL
,	NULL
Nucl	NULL
Acids	NULL
Res	NULL
12	NULL
,	NULL
7035-7056	NULL
.	NULL

K.	NULL
B.	NULL
Meyer	NULL
and	NULL
M.	NULL
Neuberger	NULL
(	NULL
1989	NULL
)	NULL
,	NULL
EMBO	NULL
J	NULL
8	NULL
,	NULL
1959-1964	NULL
.	NULL

P.	NULL
Mitchell	NULL
and	NULL
R.	NULL
Tjian	NULL
(	NULL
1989	NULL
)	NULL
,	NULL
Science	NULL
245	NULL
,	NULL
371-378	NULL
.	NULL

J.	NULL
Mizushima-Sugano	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
(	NULL
1986	NULL
)	NULL
,	NULL
Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
83	NULL
,	NULL
8511-8515	NULL
.	NULL

P.	NULL
Moreau	NULL
,	NULL
R.	NULL
Hen	NULL
,	NULL
B.	NULL
Wasylyk	NULL
,	NULL
R.	NULL
Everett	NULL
,	NULL
M.	NULL
Gaub	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
(	NULL
1981	NULL
)	NULL
,	NULL
Nucl	NULL
Acids	NULL
Res	NULL
9	NULL
,	NULL
6047-6068	NULL
.	NULL

No	NULL
evidence	NULL
for	NULL
enhancer/promoter	NULL
preference	NULL
F.	NULL
Moreau-Gachelin	NULL
,	NULL
D.	NULL
Ray	NULL
,	NULL
P.	NULL
Tambourin	NULL
and	NULL
A.	NULL
Tavitian	NULL
,	NULL
M.	NULL
J.	NULL
Klemsz	NULL
,	NULL
S.	NULL
R.	NULL
McKercher	NULL
,	NULL
A.	NULL
Celada	NULL
,	NULL
C.	NULL
Van	NULL
Beveren	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Maki	NULL
(	NULL
1990	NULL
)	NULL
,	NULL
Cell	NULL
61	NULL
,	NULL
1165-1166	NULL
.	NULL

M.	NULL
M.	NULL
Miller	NULL
,	NULL
T.	NULL
Gerster	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
(	NULL
1988a	NULL
)	NULL
,	NULL
Eur	NULL
J	NULL
Biochem	NULL
176	NULL
,	NULL
485-495	NULL
.	NULL

M.	NULL
M.	NULL
Muller	NULL
,	NULL
S.	NULL
Ruppert	NULL
,	NULL
W.	NULL
Schaffner	NULL
,	NULL
and	NULL
P.	NULL
Matthias	NULL
(	NULL
1988b	NULL
)	NULL
,	NULL
Nature	NULL
336	NULL
,	NULL
544-551	NULL
.	NULL

H-P.	NULL
Muller	NULL
,	NULL
J.	NULL
M.	NULL
Sogo	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
(	NULL
1989	NULL
)	NULL
,	NULL
Cell	NULL
58	NULL
,	NULL
767-777	NULL
.	NULL

H-P.	NULL
Miller	NULL
and	NULL
W.	NULL
Schaffner	NULL
(	NULL
1990	NULL
)	NULL
,	NULL
Trends	NULL
Genet	NULL
6	NULL
,	NULL
300-304	NULL
.	NULL

C.	NULL
Murre	NULL
,	NULL
P.	NULL
S.	NULL
McCaw	NULL
,	NULL
H.	NULL
Vaessin	NULL
,	NULL
M.	NULL
Caudy	NULL
,	NULL
L.	NULL
Y.	NULL
Jan	NULL
,	NULL
Y.	NULL
N.	NULL
Jan	NULL
,	NULL
C.	NULL
V.	NULL
Cabrera	NULL
,	NULL
J.	NULL
N.	NULL
Buskin	NULL
,	NULL
S.	NULL
D.	NULL
Hauschka	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Lassar	NULL
,	NULL
H.	NULL
Weintraub	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
(	NULL
1989	NULL
)	NULL
,	NULL
Cell	NULL
58	NULL
,	NULL
537-544	NULL
.	NULL

M.	NULL
Neuberger	NULL
(	NULL
1983	NULL
)	NULL
,	NULL
EMBO	NULL
J	NULL
2	NULL
,	NULL
1373-1378	NULL
.	NULL

P.	NULL
O'Hare	NULL
,	NULL
C.	NULL
R.	NULL
Goding	NULL
,	NULL
and	NULL
A.	NULL
Haigh	NULL
(	NULL
1988	NULL
)	NULL
,	NULL
EMBO	NULL
J	NULL
7	NULL
,	NULL
4231-4238	NULL
.	NULL

R.	NULL
D.	NULL
Palmiter	NULL
,	NULL
H.	NULL
Y.	NULL
Chen	NULL
,	NULL
and	NULL
R.	NULL
L.	NULL
Brinster	NULL
(	NULL
1982	NULL
)	NULL
,	NULL
Cell	NULL
29	NULL
,	NULL
701-710	NULL
.	NULL

L.	NULL
K.	NULL
Pape	NULL
,	NULL
J.	NULL
J.	NULL
Windle	NULL
,	NULL
E.	NULL
B.	NULL
Mougey	NULL
,	NULL
and	NULL
B.	NULL
Sollner	NULL
:	NULL
Webb	NULL
(	NULL
1989	NULL
)	NULL
,	NULL
Mol	NULL
Cell	NULL
Biol	NULL
9	NULL
,	NULL
5093-5014	NULL
.	NULL

T.	NULL
Parslow	NULL
,	NULL
S.	NULL
Jones	NULL
,	NULL
B	NULL
.	NULL

Bond	NULL
,	NULL
and	NULL
K.	NULL
Yamamoto	NULL
(	NULL
1987	NULL
)	NULL
,	NULL
Science	NULL
235	NULL
,	NULL
1498-1501	NULL
.	NULL

D.	NULL
Picard	NULL
and	NULL
W.	NULL
Schaffner	NULL
(	NULL
1984	NULL
)	NULL
,	NULL
Nature	NULL
307	NULL
,	NULL
80-82	NULL
.	NULL

D.	NULL
Picard	NULL
and	NULL
W.	NULL
Schaffner	NULL
(	NULL
1985	NULL
)	NULL
,	NULL
EMBO	NULL
J	NULL
4	NULL
,	NULL
2831-2838	NULL
.	NULL

L.	NULL
Pick	NULL
,	NULL
A.	NULL
Schier	NULL
,	NULL
M.	NULL
Affolter	NULL
,	NULL
T.	NULL
Schmidt	NULL
81	NULL
Glenewinkel	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Gehring	NULL
(	NULL
1990	NULL
)	NULL
,	NULL
Genes	NULL
Dev	NULL
4	NULL
,	NULL
1224-1239	NULL
.	NULL

M.	NULL
Ptashne	NULL
(	NULL
1986	NULL
)	NULL
,	NULL
Nature	NULL
322	NULL
,	NULL
697-701	NULL
.	NULL

C.	NULL
Queen	NULL
and	NULL
D.	NULL
Baltimore	NULL
(	NULL
1983	NULL
)	NULL
,	NULL
Cell	NULL
33	NULL
,	NULL
741-748	NULL
.	NULL

P.	NULL
Sassone-Corsi	NULL
,	NULL
L.	NULL
Ransone	NULL
,	NULL
W.	NULL
Lamph	NULL
,	NULL
and	NULL
I.	NULL
Verma	NULL
(	NULL
1988	NULL
)	NULL
,	NULL
Nature	NULL
336	NULL
,	NULL
692-695	NULL
.	NULL

M.	NULL
D.	NULL
Schatt	NULL
,	NULL
S.	NULL
Rusconi	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
(	NULL
1990	NULL
)	NULL
,	NULL
EMBO	NULL
J	NULL
9	NULL
,	NULL
481-487	NULL
.	NULL

R.	NULL
Sen	NULL
and	NULL
D.	NULL
Baltimore	NULL
(	NULL
1986	NULL
)	NULL
,	NULL
Cell	NULL
46	NULL
,	NULL
705-716	NULL
.	NULL

E.	NULL
Serfling	NULL
,	NULL
M.	NULL
Jasin	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
(	NULL
1985	NULL
)	NULL
,	NULL
Trends	NULL
Genet	NULL
1	NULL
,	NULL
224-230	NULL
.	NULL

C.	NULL
Steiner	NULL
,	NULL
M.	NULL
Muller	NULL
,	NULL
A.	NULL
Baniahmad	NULL
,	NULL
and	NULL
R.	NULL
Ren-kawitz	NULL
(	NULL
1987	NULL
)	NULL
,	NULL
Nucl	NULL
Acids	NULL
Res	NULL
15	NULL
,	NULL
4163-4178	NULL
.	NULL

M.	NULL
Tanaka	NULL
,	NULL
U.	NULL
Grossniklaus	NULL
,	NULL
W.	NULL
Herr	NULL
,	NULL
and	NULL
N.	NULL
Hernan	NULL
dez	NULL
(	NULL
1988	NULL
)	NULL
,	NULL
Genes	NULL
Dev	NULL
2	NULL
,	NULL
1764-1778	NULL
.	NULL

M.	NULL
Theisen	NULL
,	NULL
A.	NULL
Stief	NULL
,	NULL
and	NULL
A.	NULL
E.	NULL
Sippel	NULL
(	NULL
1986	NULL
)	NULL
,	NULL
EMBO	NULL
[	NULL
J	NULL
5	NULL
,	NULL
719-724	NULL
.	NULL

JP	NULL
.	NULL

Vincent	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Kassis	NULL
,	NULL
and	NULL
P.	NULL
H.	NULL
O'Farrell	NULL
(	NULL
1990	NULL
)	NULL
,	NULL
EMBO	NULL
J	NULL
9	NULL
,	NULL
2573-2578	NULL
.	NULL

L.	NULL
Wall	NULL
,	NULL
E.	NULL
de	NULL
Boer	NULL
,	NULL
and	NULL
F.	NULL
Grosveld	NULL
(	NULL
1988	NULL
)	NULL
,	NULL
Genes	NULL
Dev	NULL
2	NULL
,	NULL
1089-1100	NULL
.	NULL

G.	NULL
Westin	NULL
,	NULL
T.	NULL
Gerster	NULL
,	NULL
M.	NULL
M.	NULL
Muller	NULL
,	NULL
G.	NULL
Schaffner	NULL
,	NULL
and	NULL
W.	NULL
Schaffner	NULL
(	NULL
1987	NULL
)	NULL
,	NULL
Nucl	NULL
Acids	NULL
Res	NULL
15	NULL
,	NULL
6787-6798	NULL
.	NULL

C.	NULL
Wilson	NULL
,	NULL
R.	NULL
K.	NULL
Pearson	NULL
,	NULL
H.	NULL
J.	NULL
Bellen	NULL
,	NULL
C.	NULL
J.	NULL
O'Kane	NULL
,	NULL
U.	NULL
Grossniklaus	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Gehring	NULL
(	NULL
1989	NULL
)	NULL
,	NULL
Genes	NULL
Dev	NULL
3	NULL
,	NULL
1301-1313	NULL
.	NULL

T.	NULL
Wirth	NULL
,	NULL
L.	NULL
Staudt	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
(	NULL
1987	NULL
)	NULL
,	NULL
Nature	NULL
329	NULL
,	NULL
174-178	NULL
.	NULL

